<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-title>Pediatric Rheumatology Online Journal</journal-title><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19046457</article-id><article-id pub-id-type="pmc">2633304</article-id><article-id pub-id-type="publisher-id">1546-0096-6-20</article-id><article-id pub-id-type="doi">10.1186/1546-0096-6-20</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Milojevic</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>milojevic@peds.ucsf.edu</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Nguyen</surname><given-names>Khoa D</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kdnguyen@stanford.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Wara</surname><given-names>Diane</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>warad@peds.ucsf.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Mellins</surname><given-names>Elizabeth D</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mellins@stanford.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pediatrics, UCSF, San Francisco, CA 94143, USA</aff><aff id="I2"><label>2</label>Department of Pediatrics, Stanford University, Stanford, CA 94305, USA</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>1</day><month>12</month><year>2008</year></pub-date><volume>6</volume><fpage>20</fpage><lpage>20</lpage><ext-link ext-link-type="uri" xlink:href="http://www.ped-rheum.com/content/6/1/20"/><history><date date-type="received"><day>9</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Milojevic et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Milojevic et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Milojevic               Diana                              milojevic@peds.ucsf.edu            </dc:author><dc:title>            Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Pediatric Rheumatology 6(1): 20-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1546-0096(2008)6:1&#x0003c;20&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1546-0096</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Regulatory T cells have an important role in limiting immune reactions and are essential regulators of self-tolerance. Among them, CD4+CD25<sup>high </sup>regulatory T cells are the best-described subset. In this article, we summarize current knowledge on the phenotype, function, and development of CD4+CD25<sup>high </sup>regulatory T cells. We also review the literature on the role of these T cells in rheumatic diseases and discuss the potential for their use in immunotherapy.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Tolerance to "self" is a major immune regulatory mechanism that protects the body's own tissues from immune-mediated damages and restricts active immune responses to those against microbial invaders (Figure <xref ref-type="fig" rid="F1">1</xref>). A classical type of tolerance, called central tolerance, is the mechanism by which "forbidden clones" of lymphocytes that recognize self antigens are eliminated in the thymus during normal lymphocyte development [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. However, some lymphocyte clones with specificities for self antigens are found in animals and humans without autoimmunity [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. In addition, autoimmunity can develop in the absence of defects in central tolerance. These findings initially led to the hypothesis that peripheral tolerancemust prevent auto-aggression by self-reactive T cells that escape thymic deletion. In the 1970s and 1980s, work on peripheral tolerance focused on characterization of specific suppressor T cells, the presumed regulators of immune responses in the periphery [<xref ref-type="bibr" rid="B9">9</xref>]. However, attempts to define and isolate suppressor T cells led to conflicting results, disappointment, and near abandonment of the field. With the development of new technologies in the 1990s, compelling evidence was put forward to support the existence of cellular subsets that possess immunosuppressive activities, this time under the name regulatory T cells[<xref ref-type="bibr" rid="B10">10</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Mechanisms of immune tolerance.</p></caption><graphic xlink:href="1546-0096-6-20-1"/></fig><sec><title>Types of regulatory T cells</title><p>There are various types of regulatory T cells, including TCR&#x003b1;&#x003b2;+CD4+, TCR&#x003b1;&#x003b2;+CD8+, TCR&#x003b1;&#x003b2;+CD4-CD8-, and TCR&#x003b3;&#x003b9;+ T cells. The majority of recent research has focused on TCR&#x003b1;&#x003b2;+CD4+ regulatory T cells, of which there are several subtypes with distinct surface phenotypes, cytokine production profiles and mechanisms of immune suppression. Among the subtypes, T cells produced in the thymus and delivered to the periphery as a long-lived lineage of self-antigen-specific lymphocytes are called natural CD4+CD25<sup>high </sup>regulatory T cells (nTreg). In contrast+, CD4+ T cells that are recruited from circulating lymphocytes and acquire regulatory properties under particular conditions of stimulation are called adaptive Tcells(Figure <xref ref-type="fig" rid="F2">2</xref>). Two types of adaptive CD4+ regulatory T cells are type 1 regulatory T cells (Tr1) and T helper 3 regulatory cells (Th3). Suppressive effects of Tr1 and Th3 cells are dependent on the production of inhibitory cytokines, IL-10 and TGF-&#x003b2;, respectively [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. A third type of adaptive regulatory T cell is the CD4+CD25<sup>high </sup>T cell induced in the periphery; these are termed induced regulatory T cells (iTreg). iTreg have similar properties to thymus-generated nTreg. Both cell types are anergic and do not proliferate upon TCR stimulation. Both cell types can inhibit proliferation of CD4+CD25- T cells in a dose dependent manner. Despite their characteristic anergy, CD4+CD25<sup>high </sup>regulatory T cells cultured with anti-CD3 antibodies (for TCR stimulation) and excess IL-2 (a T cell growth factor), can proliferate and still retain their suppressive activities. CD4+CD25<sup>high </sup>regulatory T cells (nTreg and iTreg) are the subject of this review.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Different subsets of regulatory T cells.</p></caption><graphic xlink:href="1546-0096-6-20-2"/></fig></sec><sec><title>Development of CD4+CD25<sup>high </sup>regulatory T cells</title><p>NTreg arise during normal lymphocyte ontogeny in the thymus [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>], and this is thought to be the exclusive site of nTreg development in children [<xref ref-type="bibr" rid="B20">20</xref>]. NTreg represent 5&#x02013;10% of CD4+CD8- thymocytes in humans, mice, and rats. It seems likely that nTreg are positively selected through high-affinity recognition of self peptides presented by thymic stromal cells. This event, possibly together with signals from thymic dendritic cells, stimulates production of anti-apoptotic molecules to protect against negative selection. Recent data also indicate that CD4+CD25<sup>high </sup>regulatory T cells have a reciprocal developmental relationship in with Th17 cells, inflammatory T helper cells that produce IL-17 [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>Many aspects of nTreg development in the thymus, such as their site of development, their interaction with thymic epithelial cells, and their selection are still poorly understood [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Despite these uncertainties, it is clear that the transcription factor forkhead box P3 (Foxp3) plays a major role in the ontogeny and function of nTreg [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. FoxP3 is preferentially and stably expressed in peripheral nTreg, even after proliferation [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. However, the signals that induce the stable up-regulation of Foxp3 and committed regulatory function in nTreg are not known. Furthermore, recent research shows that much of the nTreg transcriptional signature is not ascribable to Foxp3. It seems that a complex regulatory mechanism upstream of Foxp3 determines nTreg lineage and is distinct from elements downstream of Foxp3 that are essential for the cell's regulatory properties [<xref ref-type="bibr" rid="B30">30</xref>]. After their thymic selection, nTreg populate peripheral tissues. They are believed to be long-lived and may repeatedly proliferate in the periphery upon encountering specific self antigens [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>]. However, their potential for continuous cell division is limited, which is thought to be associated with their diminished telomerase activity compared to CD4+CD25- T cells [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>].</p><p>The total number of CD4+CD25<sup>high </sup>regulatory T cells in human peripheral blood increases with age, despite thymic involution [<xref ref-type="bibr" rid="B36">36</xref>]. The likely explanation is the thymus-independent generation of CD4+CD25<sup>high </sup>iTreg. Several lines of evidences have suggested that induction of iTreg requires FoxP3. When a Foxp3 gene is transduced into CD4+CD25- T cells, these cells acquire CD25 surface expression and other phenotypic characteristics of nTreg. These transduced CD4+CD25<sup>high </sup>iTreg are able to inhibit proliferation and cytokine production in the effector T cells and the development of some experimental autoimmune diseases in animals [<xref ref-type="bibr" rid="B37">37</xref>]. Murine and human studies show that several cytokines are also required for generation of extra-thymic CD4+CD25<sup>high </sup>iTreg. Essential stimuli include TGF-&#x003b2; [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B41">41</xref>], IFN-&#x003b3; [<xref ref-type="bibr" rid="B42">42</xref>], anti-CD3/CD28 antibodies or antigen specific stimulation [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>], IL-4/IL-13 [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>], and thrombospondin-CD47 interaction [<xref ref-type="bibr" rid="B46">46</xref>]. Murine studies also show that tolerogenic conditions and homeostatic proliferation during lymphopenia induce the development of CD4+CD25<sup>high </sup>Foxp3+ iTreg <italic>in vivo </italic>[<xref ref-type="bibr" rid="B47">47</xref>-<xref ref-type="bibr" rid="B51">51</xref>].</p></sec><sec><title>Phenotype of CD4+CD25<sup>high </sup>regulatory T cells</title><p>No specific marker for CD4+CD25<sup>high </sup>regulatory T cells is yet known (Figure <xref ref-type="fig" rid="F3">3</xref>). Foxp3 has been considered the most reliable marker [<xref ref-type="bibr" rid="B23">23</xref>], but is intracellular and cannot be used for isolation or <italic>in vivo </italic>tracking of CD4+CD25<sup>high </sup>regulatory T cells. In addition, activation of CD4+CD25- T cells can transiently up-regulate FoxP3 expression in human cells, although this is not the case in mice [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B53">53</xref>]. Hence, FoxP3 alone may not be a specific marker for human CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B53">53</xref>].</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Surface markers associated with CD4+CD25high regulatory T cells.</p></caption><graphic xlink:href="1546-0096-6-20-3"/></fig><p>Another molecule associated with CD4+CD25<sup>high </sup>regulatory T cells is CD25, the &#x003b1; chain of the IL-2 receptor, Both nTreg and iTreg constitutively express CD25 and suppressive activity is optimal in CD4+ T cells expressing the highest levels of CD25 (approximately 2&#x02013;4% of human peripheral blood CD4+ T cells). However, CD25 by itself has limitations as a marker for CD4+CD25<sup>high </sup>regulatory T cells, as it is also up-regulated in activated effector T cells. The recent discovery of low expression of CD127 (IL-7 receptor &#x003b1;) on CD4+CD25<sup>high </sup>regulatory T cells provides further delineation of this population [<xref ref-type="bibr" rid="B54">54</xref>-<xref ref-type="bibr" rid="B56">56</xref>]. However, some regulatory CD4+ T cells that are Foxp3+CD127<sup>low </sup>express little-to-no CD25 [<xref ref-type="bibr" rid="B56">56</xref>].</p><p>Several other molecules associated with CD4+CD25<sup>high </sup>regulatory T cells have been descsribed. In humans, these cells constitutively express intracellular cytotoxic T-lymphocyte antigen 4 (CTLA-4) and glucocorticoid-induced tumor-necrosis-factor-receptor-related protein (GITR). Upon activation, they also express membrane-bound TGF-&#x003b2; and HLA-DR [<xref ref-type="bibr" rid="B57">57</xref>]. Other surface markers reportedly expressed on human CD4+CD25<sup>high </sup>regulatory T cells include CD69, CD45RA/CD45RO, CD134 (OX40), CD95, and programmed cell death-ligand 1 (PD-L1). CD4+CD25<sup>high </sup>regulatory T cells also express chemokine receptors to direct their migration to different tissues. Current data suggest that signals from various chemokines and integrin ligands determine which membrane chemokine receptors and integrins are expressed on CD4+CD25<sup>high </sup>regulatory T cells. Similar to effector T cells, CD62L (also known as L-selectin) and CCR7 are important lymph node homing molecules for CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B58">58</xref>]. The majority of CD4+CD25<sup>high </sup>regulatory T cells express CCR4 and CCR8 [<xref ref-type="bibr" rid="B59">59</xref>], but other chemokine receptors and integrin molecules, such CD103, are also present. The expression level of integrins dictates the direction of cell migration. For example, CD4+CD25<sup>high </sup>CD103- regulatory T cells preferentially migrate to lymph nodes, whereas CD4+CD25<sup>high </sup>CD103+ regulatory T cells efficiently migrate into inflammatory sites [<xref ref-type="bibr" rid="B58">58</xref>]. Most human CD4+CD25<sup>high </sup>regulatory T cells are believed to be in a late stage of differentiation. This notion is supported by their expression of activation/memory markers, as indicated above [<xref ref-type="bibr" rid="B60">60</xref>].</p><p>The absence of specific markers makes it difficult to isolate pure populations of CD4+CD25<sup>high </sup>regulatory T cells, to further characterize their phenotype. At least a small number of non-regulatory activated effector T cells usually contaminate isolated CD4+CD25<sup>high </sup>regulatory T cells, due to the overlapping expression of CD25. Thus, strategies to expand CD4+CD25<sup>high </sup>regulatory T cells for higher yield and purity have been sought. Use of IL-2, a T cell growth factor that induces proliferation of CD4+CD25<sup>high </sup>regulatory T cells <italic>in vitro</italic>, was considered. However, IL-2 also favors the expansion of non-regulatory effector T cells. Another candidate is the immunosuppressive drug rapamycin (sirolimus), used for the prevention of organ transplant rejection as well as resistant graft versus host disease (GVHD) [<xref ref-type="bibr" rid="B61">61</xref>-<xref ref-type="bibr" rid="B63">63</xref>]. Human peripheral blood CD4+CD25<sup>high </sup>regulatory T cells cultured in the presence of rapamycin survive and vigorously expand for at least 3 weeks, while effector T cells are inhibited from proliferation. This phenomenon is thought to result from differential intracellular signaling in CD4+CD25<sup>high </sup>regulatory T cells compared to CD4+CD25- effector T cells in response to rapamycin, which blocks progression from G1 into S phase in activated effectors [<xref ref-type="bibr" rid="B64">64</xref>]. The rapamycin-expanded CD4+CD25<sup>high </sup>regulatory T cells are suppressive and have the same phenotype as freshly isolated blood CD4+CD25<sup>high </sup>regulatory T cells. Thus, <italic>in vitro </italic>rapamycin may allow the generation of highly efficient CD4+CD25<sup>high </sup>regulatory T cells and better characterization of their functions for potential clinical use [<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B66">66</xref>].</p></sec><sec><title>CD4+CD25<sup>high </sup>regulatory T cell function</title><p>A key characteristic of CD4+CD25<sup>high </sup>regulatory T cells is their <italic>in vitro </italic>anergy. In contrast to CD4+CD25- T cells, which proliferate upon receiving T cell receptor (TCR) stimulation, CD4+CD25<sup>high </sup>regulatory T cells are unresponsive to this proliferative signal and do not produce IL-2. However, CD4+CD25<sup>high </sup>regulatory T cells cultured with anti-CD3 antibodies for TCR stimulation and excessexogenous IL-2 overcome anergy and proliferate; blocking IL-2 inhibits this phenomemon [<xref ref-type="bibr" rid="B67">67</xref>]. The anergic state of CD4+CD25<sup>high </sup>regulatory T cells can also be overcome by anti-CD28 costimulation or interaction with mature dendritic cells [<xref ref-type="bibr" rid="B68">68</xref>-<xref ref-type="bibr" rid="B70">70</xref>]. Interestingly, recent studies suggest that CD4+CD25<sup>high </sup>regulatory T cells are not anergic <italic>in vivo</italic>, but have a high turnover rate [<xref ref-type="bibr" rid="B71">71</xref>,<xref ref-type="bibr" rid="B72">72</xref>].</p><p>The second cardinal feature of CD4+CD25<sup>high </sup>regulatory T cells is their ability to suppress immune responses [<xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B73">73</xref>]. Suppression occurs when CD4+CD25<sup>high </sup>regulatory T cells are activated with antigens recognized by their specific TCR, but can be maintained without further TCR stimulation [<xref ref-type="bibr" rid="B74">74</xref>]. Thus, suppressive activity is antigen-nonspecific. However, CD4+CD25<sup>high </sup>regulatory T cells that share the same antigenic specificity with effector cells are more suppressive. Similarly, allogeneic CD4+CD25<sup>high </sup>regulatory T cells are suppressive, but autologous CD4+CD25<sup>high </sup>regulatory T cells are more potent suppressors. Some studies suggest that CD4+CD25<sup>high </sup>regulatory T cells inhibit proliferation of effector CD4+CD25- T cells and CD8+ T cells by arresting the proliferation of these cells at G1-S interphase of the cell cycle [<xref ref-type="bibr" rid="B75">75</xref>]. Interestingly, the addition of exogenous IL-2 does not overcome the suppression, suggesting unresponsiveness at the level of the IL-2 receptor [<xref ref-type="bibr" rid="B72">72</xref>]</p><p>Contact-dependent suppression by CD4+CD25<sup>high </sup>regulatory T cells has been reported to occur via CTLA-4 signaling: CTLA-4 blockade leads to diminished suppression of effector T cell proliferation by CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B76">76</xref>,<xref ref-type="bibr" rid="B77">77</xref>]. Recent studies have suggested that multiple CTLA-4 associated pathways could mediate suppression by CD4+CD25<sup>high </sup>regulatory T cells. Preferential engagement of CTLA-4, instead of CD28, with CD80/CD86 may provide a negative proliferative signal [<xref ref-type="bibr" rid="B78">78</xref>]. Alternatively, CTLA-4 on CD4+CD25<sup>high </sup>regulatory T cells may signal dendritic cells to produce the immunosuppressive cytokines, IL-10 and TGF-&#x003b2; [<xref ref-type="bibr" rid="B79">79</xref>]. In a novel mechanism, suggested by results of Fallarino et al., CTLA-4 signals dendritic cells to produce high levels of the enzyme indoleamine, which in turn breaks down tryptophan, an amino acid important for T cell proliferation [<xref ref-type="bibr" rid="B80">80</xref>], and consequentially inhibits the proliferation of effector T cells.</p><p>While the main targets of suppression by CD4+CD25<sup>high </sup>regulatory T cells are innate and adaptive immune cells [<xref ref-type="bibr" rid="B81">81</xref>], these regulatory T cells also participate in immune responses against infectious agents [<xref ref-type="bibr" rid="B82">82</xref>], malignant cells [<xref ref-type="bibr" rid="B83">83</xref>], and allogeneic organ and stem-cell grafts [<xref ref-type="bibr" rid="B84">84</xref>]. Although CD4+CD25<sup>high </sup>regulatory T cells regulate both Th1 and Th2 immune responses, Th2 cells may partially escape this suppressive activity via their ability to respond to growth factors other than IL-2, such as IL-4, IL-7, and IL-9 [<xref ref-type="bibr" rid="B85">85</xref>]. In contrast, the proliferation of Th1 cells is only restored by the administration of IL-15 [<xref ref-type="bibr" rid="B85">85</xref>]. In mice, the depletion of CD4+CD25<sup>high </sup>regulatory T cells prevents antigen-induced Th2 differentiation by increasing the differentiation of Th1 cells [<xref ref-type="bibr" rid="B86">86</xref>,<xref ref-type="bibr" rid="B87">87</xref>]. Under appropriate conditions, CD4+CD25<sup>high </sup>regulatory T cells are able to confer suppressive capacity on CD4+CD25- T cells, converting them to either Th3 or Tr1 cells [<xref ref-type="bibr" rid="B88">88</xref>,<xref ref-type="bibr" rid="B89">89</xref>].</p></sec><sec><title>CD4+CD25<sup>high </sup>regulatory T cells and autoimmunity</title><p>Several autoimmune disorders have been linked to physical and genetic alterations in thymus that disrupt the development of nTreg. Thymectomized neonatal mice are deficient in CD4+CD25<sup>high </sup>regulatory T cells and develop multi-organ autoimmune disease, which can be overcome by the adoptive transfer of CD25+ thymocytes from normal mice [<xref ref-type="bibr" rid="B90">90</xref>,<xref ref-type="bibr" rid="B91">91</xref>]. Children with thymic hypoplasia as a result of the 22.q2 deletion syndrome display impaired CD4+CD25<sup>high </sup>regulatory T cell generation and have an increased risk of developing an autoimmune disorder [<xref ref-type="bibr" rid="B92">92</xref>]. Mutations in Foxp3 result in the scurfy phenotype in mice. Foxp3 mutant "scurfy" mice and Foxp3-null mice lack CD4+CD25<sup>high </sup>regulatory T cells and die of a lymphoproliferative-wasting disease, likely due to uncontrolled expansion of effector T lymphocytes. Adoptive transfer of CD4+CD25<sup>high </sup>regulatory T cells into neonatal Foxp3-null or scurfy mice protects them temporarily from disease [<xref ref-type="bibr" rid="B92">92</xref>,<xref ref-type="bibr" rid="B93">93</xref>].</p><p>Human patients with Foxp3 gene mutations develop IPEX syndrome, a potentially fatal disorder, characterized by immune dysregulation, polyendocrinopathy, and enteropathy (Table <xref ref-type="table" rid="T1">1</xref>) [<xref ref-type="bibr" rid="B94">94</xref>-<xref ref-type="bibr" rid="B96">96</xref>]. IPEX CD4+CD25<sup>high </sup>regulatory T cells are less suppressive, although their surface phenotype and levels in peripheral blood remain normal [<xref ref-type="bibr" rid="B97">97</xref>]. Consequently, it is suggested that functional insufficiency rather than defective differentiation of CD4+CD25<sup>high </sup>regulatory T cells may occur in these patients. Allogeneic bone marrow transplantation in IPEX subjects is effective in correcting Foxp3 associated dysfunctions [<xref ref-type="bibr" rid="B98">98</xref>], and clinical recovery accompanies regeneration of functionally competent CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B99">99</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of IPEX Syndrome <sup>#&#x000a7;</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Organ system</bold></td><td align="center"><bold>Manifestations*</bold></td></tr></thead><tbody><tr><td align="center">Endocrine</td><td align="center">Insulin dependent diabetes mellitus<break/>Thyroid dysfunction<break/>Parathyroid hormone resistance</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center">Gastrointestinal</td><td align="center">Autoimmune enteropathy<break/>Diarrhea<break/>Villous atrophy, failure to thrive</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center">Skin</td><td align="center">Eczema<break/>Ichthyosiform dermatitis<break/>Exfoliative dermatitis</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center">Infectious disease</td><td align="center">Exaggerated response<break/>to viral infections<break/>Frequent infections</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="center">Immune dysregulation</td><td align="center">Increased IgE, intermittent eosinophilia<break/>Skewing of T lymphocytes to Th2 phenotype<break/>Hemolytic anemia<break/>Immune thrombocytopenia<break/>Coagulopathy</td></tr></tbody></table><table-wrap-foot><p><sup># </sup>Alternative names: XLAAD (X-linked autoimmunity allergic dysregulation syndrome); insulin dependent diabetes mellitus-secretory diarrhea syndrome; XPID (Polyendocrinopathy, immune dysfunction, diarrhea, X-linked)</p><p><sup>&#x000a7; </sup>Treatment: immunosuppression (Cyclosporine A), allogeneic bone marrow transplantation</p><p>* Manifestations of the disease are highly variable</p></table-wrap-foot></table-wrap><p>In addition to IPEX, many more common polygenic autoimmune disorders, including multiple sclerosis, type 1 diabetes, are hypothesized to have abnormalities in CD4+CD25<sup>high </sup>regulatory T cell function [<xref ref-type="bibr" rid="B100">100</xref>-<xref ref-type="bibr" rid="B105">105</xref>]. Below, we consider this hypothesis and discuss findings from studies of these cells in rheumatic diseases. Across the spectrum of autoimmune diseases, it is not yet clear whether changes in these cells are primary or secondary to disease.</p></sec><sec><title>CD4+CD25<sup>high </sup>regulatory T cells in rheumatic diseases</title><p>In rheumatic diseases, most studies have focused on CD4+CD25<sup>high </sup>regulatory T cells, while the roles of other regulatory T cell types remain unclear (Table <xref ref-type="table" rid="T2">2</xref>). Early attempts to characterize CD4+CD25<sup>high </sup>regulatory T cells were flawed due to use of high surface expression of CD25 as the single cell marker and the resulting inclusion of variable numbers of activated T effector cells over the course of disease. In addition, levels and/or activity of CD4+CD25<sup>high </sup>regulatory T cells are influenced by different immunosuppressive treatments. Therefore, future studies that employ a better combination of markers (e.g. CD4, CD25, and CD127) and consider medication status and disease severity in the analysis will be important. Nonetheless, current studies of CD4+CD25<sup>high </sup>regulatory T cells in rheumatic diseases provide the scientific foundation for further research.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>CD4+CD25<sup>high </sup>regulatory T cells in rheumatic diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Disease</bold></td><td align="left"><bold>Abnormalities associated with regulatory T cells</bold></td><td align="left"><bold>Authors</bold></td></tr></thead><tbody><tr><td align="left"><bold>JIA</bold></td><td align="left">1) &#x02193; numbers in extended oligoarticular JIA.<break/>2) HSP epitopes induce &#x02191; numbers in synovial fluid.<break/>3) ASCT induces restoration of normal numbers and immune tolerance.<break/>4) Regulatory T cells from inflamed joints express CD27.</td><td align="left">1) DeKleer et al., 2004 (106).<break/>2) Massa et al., 2007 (109).<break/>3) DeKleer et al., 2006 (110).<break/>4) Ruprecht et al., 2005 (111).</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>RA</bold></td><td align="left">1) No change in numbers in peripheral blood, &#x02191; numbers in synovial fluid.<break/>2) Anti-TNF-&#x003b1; treatment does not induce changes in numbers and function*.<break/>3) Anti-TNF-&#x003b1; treatment induces &#x02191; in numbers and function *.<break/>4) Synovial T cells are more resistant to suppression.<break/>5) &#x02191; numbers of CCR5+ CXCR4+ regulatory T cells in synovial fluid.<break/>6) Imbalance between IFN-&#x003b3; producing cells and regulatory T cell numbers.</td><td align="left">1) Cao et al., 2003 (108), Mottonen et al., 2005 (119).<break/>2) Dombrecht et al., 2006 (115).<break/>3) Ehrenstein et al., 2004 (117).<break/>4) van Amelsfort et al., 2004 (116).<break/>5) Jiao et al., 2007 (120).<break/>6) Behrens et al., 2007 (121).</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>SLE</bold></td><td align="left">1) &#x02193; numbers during active disease*.<break/>2) No change in numbers during clinical remission.<break/>3) &#x02191; numbers*.<break/>4) Treatment does not induce changes in numbers*.<break/>5) Corticosteroid treatment induces &#x02191; numbers*.<break/>6) IFN-&#x003b1; producing cells block suppressive function.<break/>7) Positive correlation between numbers and disease severity*.<break/>8) Inverse correlation between numbers and disease severity*.<break/>9) Reversible functional defect in active disease.</td><td align="left">1) Liu et al., 2004 (126); Mellor-Pita et al., 2006 (127).<break/>2) Crispin et al., 2004 (128).<break/>3) Azab et al., 2008 (129).<break/>4) Cepika et al, 2007 (131)<break/>5) Valencia et al., 2007 (132).<break/>6) Yan et al., 2008 (134).<break/>7) Mellor-Pita et al., 2006 (127).<break/>8) Lin et al., 2007 (130).<break/>9) Barath et al., 2007 (135).</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Spondylo-arthropathy</bold></td><td align="left">1) No change in numbers and function.</td><td align="left">1) Cao et al., 2003 (108).</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Kawasaki disease</bold></td><td align="left">1) &#x02193; numbers in active disease; normalized numbers in defervescense.</td><td align="left">1) Furuno et al., 2004 (138).</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Sjogren's syndrome</bold></td><td align="left">1) &#x02191; numbers*.<break/>2) &#x02193; numbers*.</td><td align="left">1) Gottenberg et al., 2005 (136).<break/>2) Li et al., 2007 (137).</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Sarcoidosis</bold></td><td align="left">1) &#x02191; numbers; insufficient inhibition of TNF-&#x003b1; production.<break/>2) &#x02193; regulatory T cell-associated genes in broncho-aveolar fluid T cells.</td><td align="left">1) Miyara et al., 2003 (139).<break/>2) Idali et al., 2008 (140).</td></tr></tbody></table><table-wrap-foot><p>* Conflicting results.</p></table-wrap-foot></table-wrap></sec><sec><title>Juvenile idiopathic arthritis (JIA)</title><p>Research on CD4+CD25<sup>high </sup>regulatory T cells in juvenile idiopathic arthritis (JIA) has revealed distinct abnormalities in function and distribution in various disease subtypes. De Kleer et al. found reduced numbers of circulating CD4+CD25<sup>high </sup>regulatory T cells in extended oligoarticular JIA, compared to persistent oligoarticular JIA [<xref ref-type="bibr" rid="B106">106</xref>]. The numbers of CD4+CD25<sup>high </sup>Foxp3+ regulatory T cells in the synovial fluid of inflamed joints were comparable, but more CD4+CD25<sup>intermediate </sup>Foxp3+ regulatory T cells were present in persistent vs. extended oligoarticular JIA. Synovial fluid CD4+CD25<sup>high </sup>regulatory T cells had more potent <italic>in vitro </italic>suppressive effects compared to their peripheral blood counterparts, suggesting possible functional enhancement of these cells in the joints. In addition, CD4+CD25<sup>high </sup>regulatory T cells more easily suppress peripheral blood CD4+CD25- T effector cells than T effectors from synovial fluid, consistent with <italic>in vitro </italic>findings on the effects of IL-1 and IL-6 on susceptibility to suppression [<xref ref-type="bibr" rid="B107">107</xref>]. The authors conclude that CD4+CD25<sup>high </sup>regulatory T cells cannot prevent disease development, but synovial CD4+CD25<sup>high </sup>regulatory T cells may contribute to reversal of ongoing inflammation in persistent oligoarticular JIA [<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B108">108</xref>].</p><p>In another study of synovial CD4+CD25<sup>high </sup>regulatory T cells in persistent and extended oligoarticular JIA, Massa et al. demonstrated that certain epitopes of human HSP increase the frequency of CD4+CD25<sup>high </sup>regulatory T cells and induce Foxp3 expression [<xref ref-type="bibr" rid="B109">109</xref>]. Reactivity of CD4+CD25<sup>high </sup>regulatory T cells to these human HSP epitopes appears to influence regulation of inflammation in oligoarticular JIA [<xref ref-type="bibr" rid="B109">109</xref>].</p><p>In systemic JIA, circulating CD4+CD25<sup>high </sup>regulatory T cell frequency was reported to be lower than healthy controls [<xref ref-type="bibr" rid="B110">110</xref>]. Studies from our laboratory showed that circulating CD4+CD25<sup>high </sup>CD127<sup>lo/- </sup>regulatory T cell numbers are normal, but their <italic>in vitro </italic>suppressive function is lower than that of healthy controls (unpublished data). This defect in CD4+CD25<sup>high </sup>regulatory T cell-mediated suppression does not appear to result from a deficiency of CD45RA+ na&#x000ef;ve cells, the more suppressive subset of CD4+CD25<sup>high </sup>CD127<sup>lo/- </sup>regulatory T cells (unpublished data). In contrast, we find reduced levels of circulating CD4+CD25<sup>high </sup>regulatory T cells in polyarticular JIA (unpublished data).</p><p>Ruprecht et al. [<xref ref-type="bibr" rid="B111">111</xref>] also investigated CD4+CD25<sup>high </sup>regulatory T cells in synovial fluid of patients with JIA. They found that CD4+CD25<sup>high </sup>regulatory T cells expressing surface CD27 exhibit a higher level of Foxp3 and have stronger suppressive activity. They concluded that, used in conjunction with CD25, CD27 is a useful marker to distinguish regulatory from effector T cells in inflamed tissues. However, others have disputed the specificity of CD27 as a CD4+CD25<sup>high </sup>regulatory T cell marker [<xref ref-type="bibr" rid="B112">112</xref>].</p><p>Another important issue is how various JIA treatments affect CD4+CD25<sup>high </sup>regulatory T cell distribution and function. It was reported that methotrexate and corticosteroids do not influence the frequency or activity of these cells in JIA [<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B110">110</xref>]. De Kleer et al. observed normalization of levels of circulating CD4+CD25<sup>high </sup>regulatory T cell after autologous stem cell transplantation (ASCT), perhaps from the preferential homeostatic expansion of CD4+CD25<sup>high </sup>regulatory T cells during the lymphopenic phase of immune reconstitution. They postulated that ASCT reprograms auto-reactive T cells and restores the immune regulatory network of CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B110">110</xref>].</p></sec><sec><title>Rheumatoid arthritis (RA)</title><p>Reported data on frequency and activity of CD4+CD25<sup>high </sup>regulatory T cells in rheumatoid arthritis (RA) are conflicting. Liu et al. found the quantities and functional properties of CD4+CD25<sup>high </sup>regulatory T cells in peripheral blood of RA patients to be comparable to healthy control subjects [<xref ref-type="bibr" rid="B113">113</xref>,<xref ref-type="bibr" rid="B114">114</xref>], while Cao et al. reported a decreased frequency of CD4+CD25<sup>high </sup>regulatory T cells in peripheral blood of RA subjects [<xref ref-type="bibr" rid="B114">114</xref>]. Some studies found that treatment with methotrexate, hydroxychloroquine, anti-TNF-&#x003b1;, and systemic/intra-articular steroids does not influence the abundance or suppressive function of CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B115">115</xref>-<xref ref-type="bibr" rid="B118">118</xref>], while others reported increased levels and suppressive function with TNF-&#x003b1; blockade [<xref ref-type="bibr" rid="B117">117</xref>,<xref ref-type="bibr" rid="B118">118</xref>].</p><p>Nevertheless, there is a consensus that synovial fluid in inflamed joints is enriched in CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B113">113</xref>,<xref ref-type="bibr" rid="B114">114</xref>,<xref ref-type="bibr" rid="B119">119</xref>]. These synovial CD4+CD25<sup>high </sup>regulatory T cells express increased levels of inflammation-related chemokine receptors, such as CCR4, CCR5, and CXCR4 [<xref ref-type="bibr" rid="B120">120</xref>]. Like findings in JIA, evidence for the increased resistance of RA synovial T effector cells to suppression by CD4+CD25<sup>high </sup>regulatory T cells has been reported [<xref ref-type="bibr" rid="B116">116</xref>]. Behrens et al. linked CD4+CD25<sup>high </sup>regulatory T cell dysfunction in RA to a disturbance in the homeostatic relationship between CD4+CD25<sup>high </sup>regulatory T cells and Th1 cells in the synovium. CD4+CD25<sup>high </sup>regulatory T cells from RA subjects are capable of suppressing the production of IFN-&#x003b3; by synovial membrane Th1 lymphocytes [<xref ref-type="bibr" rid="B121">121</xref>]. However, the ratio of CD4+CD25<sup>high </sup>regulatory T cells to IFN-&#x003b3; producing cells is lower in the synovial membrane than in synovial fluid or blood. The authors suggest that the local imbalance between Th1 and CD4+CD25<sup>high </sup>regulatory T cells may be responsible for repeated rheumatic flares and could be a target for future treatments [<xref ref-type="bibr" rid="B121">121</xref>].</p></sec><sec><title>Systemic lupus erythematosus (SLE)</title><p>Findings that central tolerance remains intact in murine models of SLE suggest a critical breakdown of peripheral tolerance in this disease [<xref ref-type="bibr" rid="B122">122</xref>-<xref ref-type="bibr" rid="B124">124</xref>]. Consistent with this possibility, most studies in human SLE indicate that CD4+CD25<sup>high </sup>regulatory T cell distribution is altered in association with active disease. Numbers of circulating CD4+CD25<sup>high </sup>regulatory T cells decrease in patients with active SLE [<xref ref-type="bibr" rid="B125">125</xref>-<xref ref-type="bibr" rid="B127">127</xref>] while clinical remission is associated with elevated or normal CD4+CD25<sup>high </sup>regulatory T cell frequency [<xref ref-type="bibr" rid="B128">128</xref>-<xref ref-type="bibr" rid="B131">131</xref>]. A single study reported that disease activity in SLE correlates positively with the numbers of CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B131">131</xref>].</p><p>In a study of CD4+CD25<sup>high </sup>regulatory T cell function, Vallencia et al. claimed that a reversible defect occurs in patients with SLE. CD4+CD25<sup>high </sup>regulatory T cells from active but not inactive SLE patients were deficient in <italic>in vitro </italic>suppressive activity and had decreased Foxp3 mRNA and protein [<xref ref-type="bibr" rid="B132">132</xref>,<xref ref-type="bibr" rid="B133">133</xref>]. Opposite findings of increased Foxp3 expression in active disease were reported in one study of pediatric SLE [<xref ref-type="bibr" rid="B133">133</xref>]. Yan et al. found no difference in Foxp3 expression in CD4+CD25<sup>high </sup>regulatory T cells of SLE patients [<xref ref-type="bibr" rid="B134">134</xref>]. However, decreased suppressive function of CD4+CD25<sup>high </sup>regulatory T cells appeared to be a consequence of inhibition by IFN-activated autologous antigen presenting cells. These cells could also inhibit the function of CD4+CD25<sup>high </sup>regulatory T cells from healthy control subjects [<xref ref-type="bibr" rid="B135">135</xref>].</p></sec><sec><title>Other rheumatic diseases</title><p>The work on CD4+CD25<sup>high </sup>regulatory T cells in other rheumatic diseases is limited to date. In primary Sjogren syndrome, Gottenberg et al. reported an increase in circulating CD4+CD25<sup>high </sup>regulatory T cells, and no change in levels with methotrexate or corticosteroid treatment [<xref ref-type="bibr" rid="B136">136</xref>]. However, a more recent report argues that the numbers of circulating CD4+CD25<sup>high </sup>regulatory T cells in patients with Sjogren syndrome decrease [<xref ref-type="bibr" rid="B137">137</xref>].</p><p>In Kawasaki disease, Furuno et al. found that during the active phase of the disease, the number of circulating CD4+CD25<sup>high </sup>regulatory T cells is reduced compared to patients with infectious causes of febrile illness, whose CD4+CD25<sup>high </sup>regulatory T cell numbers are higher than in healthy subjects. In defervesce phase of the disease, the number of CD4+CD25<sup>high </sup>regulatory T cells in patients with Kawasaki disease increases to/or above normal levels, while CD4+CD25<sup>high </sup>regulatory T cells in patients with infectious febrile disease decrease to normal levels [<xref ref-type="bibr" rid="B138">138</xref>].</p><p>In spondyloarthropathy, a single study by Cao et al. found normal levels of circulating CD4+CD25<sup>high </sup>regulatory T cells, but a higher proportion of CD4+CD25<sup>high </sup>regulatory T cells in synovial fluid of inflamed joints than in peripheral blood [<xref ref-type="bibr" rid="B114">114</xref>].</p><p>In sarcoidosis, Miyara et al. showed an increase in frequency of CD4+CD25<sup>high </sup>regulatory T cells in sarcoid granulomas, bronchoalveolar lavage fluid (BALF), and peripheral blood of patients with active disease. The cells reportedly exhibit powerful anti-proliferative activity, but cannot completely inhibit TNF-&#x003b1; production. The authors conclude that although sarcoidosis is associated with global CD4+CD25<sup>high </sup>regulatory T cell amplification, the cells are functionally insufficient to control local inflammation [<xref ref-type="bibr" rid="B139">139</xref>]. In contrast, Idali et al. [<xref ref-type="bibr" rid="B140">140</xref>] found decreased frequency of Foxp3+ cells among BALF and blood CD4+ cells in sarcoidosis patients.</p></sec><sec><title>Mechanistic issues</title><p>Current data indicate that reduced numbers of circulating CD4+CD25<sup>high </sup>regulatory T cells is not a general finding in rheumatic diseases, while reduced function is more commonly found. Several hypothetical defects in CD4+CD25<sup>high </sup>regulatory T cell function that could lead to autoimmunity have been proposed [<xref ref-type="bibr" rid="B141">141</xref>]. However, data pointing to a secondary effect on CD4+CD25<sup>high </sup>regulatory T cells in autoimmune disorders have also emerged. The example of SLE is illustrative. Compromised function could result from direct interaction between SLE-associated auto-antigens and their cognate ligands on CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B142">142</xref>]. Alternatively, endogenous stimulants in SLE may activate antigen presenting cells to produce alpha-interferon and related factors that inhibit CD4+CD25<sup>high </sup>regulatory T cell activity [<xref ref-type="bibr" rid="B134">134</xref>]. Pro-inflammatory factors associated with autoimmunity, such as IL-1, IL-6, and TNF-&#x003b1;, also can inhibit CD4+CD25<sup>high </sup>regulatory T cell function [<xref ref-type="bibr" rid="B143">143</xref>-<xref ref-type="bibr" rid="B145">145</xref>]. The resolution of this issue is central to a full understanding of autoimmunity.</p><p>Increased suppressive potency of CD4+CD25<sup>high </sup>regulatory T cells at sites of inflammation has been reported in several diseases. The relative importance of circulating versus tissue CD4+CD25<sup>high </sup>regulatory T cells requires more study. One attractive possibility is that tissue CD4+CD25<sup>high </sup>regulatory T cells may be more antigen-specific, and consequentially more suppressive [<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B116">116</xref>] while circulating CD4+CD25<sup>high </sup>regulatory T cells may be recruited to different tissues in response to inflammatory conditions [<xref ref-type="bibr" rid="B146">146</xref>], and non-specifically augment suppression. The occasionally reported reduction in numbers of CD4+CD25<sup>high </sup>regulatory T cells in the circulation may result from their recruitment to sites of inflammation. However, expansion of tissue localized and circulating CD4+CD25<sup>high </sup>regulatory T cells may occur during autoimmune-associated inflammation [<xref ref-type="bibr" rid="B116">116</xref>]. Thus, CD4+CD25<sup>high </sup>regulatory T cells may be actively recruited or be generated de novo at sites of inflammation (or both). It is anticipated that the development of new technologies that allow in vivo tracking of circulating CD4+CD25<sup>high </sup>regulatory T cells will advance our current understanding of migratory and suppressive potentials of different subsets of CD4+CD25<sup>high </sup>regulatory T cells. Finally, the potent suppressive activity of CD4+CD25<sup>high </sup>regulatory T cells at inflammatory sites is usually insufficient to control inflammation. One probable explanation is that the presence of inflammatory cytokines at these sites makes effector T cells more resistant to suppression. In addition, the recently reported induction of highly inflammatory Th17 cells from CD4+CD25<sup>high </sup>regulatory T cells that are not terminally differentiated [<xref ref-type="bibr" rid="B147">147</xref>] suggests that the latter may, under certain conditions, potentiate rather than suppress inflammation.</p></sec><sec><title>CD4+CD25<sup>high </sup>regulatory T cells as a treatment in autoimmune and rheumatic diseases</title><p>There is a need to carefully control the size of the CD4+CD25<sup>high </sup>regulatory T cell population <italic>in vivo </italic>to achieve a balance between the necessity to suppress auto-reactivity and the ability to allow appropriate responses to foreign and tumor antigens. Little is known of the mechanisms of this control; however, the alterations in distribution and function of CD4+CD25<sup>high </sup>regulatory T cells in autoimmune and rheumatic diseases suggest a role for the therapeutic use of these cells. In mice with collage-induced arthritis, depletion of CD4+CD25<sup>high </sup>regulatory T cells causes rapid progression, and the transfer of isolated and <italic>ex vivo</italic>-proliferated CD4+CD25<sup>high </sup>regulatory T cells can reverse early joint damage [<xref ref-type="bibr" rid="B148">148</xref>]. Administration of CD4+CD25<sup>high </sup>regulatory T cell also yields improvement in murine models of colitis, autoimmune encephalomyelitis, diabetes, and allogeneic transplantion [<xref ref-type="bibr" rid="B149">149</xref>-<xref ref-type="bibr" rid="B152">152</xref>].</p><p>Human research has shown that some established therapies may promote CD4+CD25<sup>high </sup>regulatory T cell development and survival <italic>in vivo</italic>. For instance, monoclonal antibody to CD20 (rituximab), which depletes B cells, leads to a selective increase in CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B153">153</xref>]. Polyclonal antibody therapies, such as anti-lymphocyte serum (ALS) and anti-thymocyte globulin (ATG), have been shown to preferentially deplete T effector cells, and induce CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B154">154</xref>,<xref ref-type="bibr" rid="B155">155</xref>]. As described above, rapamycin preferentially expands CD4+CD25<sup>high </sup>regulatory T cells. Therefore, a major therapeutic effect of rapamycin may be the induction of tolerogenic CD4+CD25<sup>high </sup>regulatory T cells <italic>in vivo</italic>.</p><p>Besides these established therapies, recent research has focused on cytokine related therapies to modulate CD4+CD25<sup>high </sup>regulatory T cell function. Among candidate cytokines are growth factors in the IL-2 family. These cytokines signal via STAT5, the homeostatic pathway that regulates CD4+CD25<sup>high </sup>regulatory T cell function. Several studies have reported that these cytokines enhance immune regulation by CD4+CD25<sup>high </sup>regulatory T cells. For instance, IL-7 and IL-15 are involved in the preservation of optimal suppressive function by CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B156">156</xref>]. In addition, IL-15 administration alone induces <italic>de novo </italic>generation of CD4+CD25<sup>high </sup>regulatory T cells [<xref ref-type="bibr" rid="B157">157</xref>]. The newly identified IL-35 has been shown to trigger CD4+CD25<sup>high </sup>regulatory T cell expansion and subsequent immune suppression [<xref ref-type="bibr" rid="B158">158</xref>]. However, the specificity of these cytokines for CD4+CD25<sup>high </sup>regulatory T cells needs to be further examined to avoid undesirable expansion of effector T cells.</p><p>In contrast to T cell growth factors, pro-inflammatory cytokines have been shown to inhibit function of CD4+CD25<sup>high </sup>regulatory T cells, possibly via promotion of Th17 development [<xref ref-type="bibr" rid="B159">159</xref>]. Therefore, anti-TNF-&#x003b1;, anti-IL1, anti-IL6, and anti-IL-21 therapies may affect inflammation not only by direct inhibition of the pro-inflammatory cytokines but also by reestablishment of immune regulation by CD4+CD25<sup>high </sup>regulatory T cells. On the other hand, short term treatment with high dose CTLA-4Ig (abatacept), which has been shown to have anti-inflammatory properties in arthritis, leads to a precipitous loss of CD4+CD25<sup>high </sup>regulatory T cells and, in some animal models, exacerbation of autoimmunity [<xref ref-type="bibr" rid="B160">160</xref>].</p><p>Direct transfusion of CD4+CD25<sup>high </sup>regulatory T cell in humans is starting to be explored as a therapy. We are aware of two early trials in patients post stem cell transplantation (SCT). In patients with allogeneic SCT, Matthias Edinger and his team from the Department of Hematology and Oncology at the University Hospital of Regensburg, Germany are conducting a phase I clinical trial (safety and feasibility) using CD4+CD25<sup>high </sup>regulatory T cells-enriched lymphocyte products (personal communication). Patients with a high risk of relapse after allogeneic SCT are preemptively treated with donor T cells enriched with 50&#x02013;60% of CD4+CD25<sup>high </sup>regulatory T cells, in order to reduce GVHD. Eight patients have been treated so far without complications. A trial using third party cord blood CD4+CD25<sup>high </sup>regulatory T cell in patients with SCT has been recently initiated at the University of Minnesota (Dr. B. Balazar, personal communication). We are not aware of any established clinical trials in autoimmune diseases, although CD4+CD25<sup>high </sup>regulatory T cell therapy will possibly be initiated in type 1 diabetes in the near future.</p><p>Despite encouraging data from animal models and early human trials, a number of issues must be resolved for optimal use of CD4+CD25<sup>high </sup>regulatory T cells as a therapy [<xref ref-type="bibr" rid="B161">161</xref>,<xref ref-type="bibr" rid="B162">162</xref>]. Firstly, there are likely to be differences in the specific role of CD4+CD25<sup>high </sup>regulatory T cells in particular diseases, and these must be elucidated. Secondly, CD4+CD25<sup>high </sup>regulatory T cell-specific surface markers remain elusive, which hampers the isolation of pure populations of CD4+CD25<sup>high </sup>regulatory T cells. Third, the use of autologous CD4+CD25<sup>high </sup>regulatory T cell clones for particular auto-antigens would increase the effectiveness and decrease potential side effects of "bystander" suppression. This will require techniques for identifying and expanding antigen specific clones of CD4+CD25<sup>high </sup>regulatory T cells. Recent successes with CD4+CD25<sup>high </sup>regulatory T cell expansion using rapamycin are promising in this regard [<xref ref-type="bibr" rid="B163">163</xref>,<xref ref-type="bibr" rid="B164">164</xref>]. Lastly, the fate of transfused CD4+CD25<sup>high </sup>regulatory T cells <italic>in vivo </italic>is not fully known. In the unlikely event that CD4+CD25<sup>high </sup>regulatory T cells expand into tumor/effector cells or simply become broadly immunosuppressive, there needs to be a way to eliminate them from the body. Future therapies may require the use of "designer" CD4+CD25<sup>high </sup>regulatory T cells that have been modified by gene transfer to selectively express preferred proteins including antigen specific TCR, homing receptors, cytokines, and "suicide" genes [<xref ref-type="bibr" rid="B161">161</xref>,<xref ref-type="bibr" rid="B162">162</xref>]. Nevertheless, the manipulation of CD4+CD25<sup>high </sup>regulatory T cell function shows great promise as a novel therapeutic option in autoimmune and rheumatic diseases.</p></sec></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>DM has formulated the concept and design of the manuscript and has written the review. KDN critically revised the initial manuscript and created the figures. DW has been involved in revising the manuscript. EDM has made critical contributions to the concept, design, and revision of the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work is supported by the American College of Rheumatology REF award to Diana Milojevic.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kappler</surname><given-names>JW</given-names></name><name><surname>Roehm</surname><given-names>N</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name></person-group><article-title>T cell tolerance by clonal elimination in the thymus</article-title><source>Cell</source><year>1987</year><volume>49</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">3494522</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kisielow</surname><given-names>P</given-names></name><name><surname>Bluthmann</surname><given-names>H</given-names></name><name><surname>Staerz</surname><given-names>UD</given-names></name><name><surname>Steinmetz</surname><given-names>M</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name></person-group><article-title>Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes</article-title><source>Nature</source><year>1988</year><volume>333</volume><fpage>742</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">3260350</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>Venanzi</surname><given-names>ES</given-names></name><name><surname>Klein</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Berzins</surname><given-names>SP</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name><name><surname>Bronson</surname><given-names>R</given-names></name><name><surname>Dierich</surname><given-names>A</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><article-title>Projection of an immunological self shadow within the thymus by the aire protein</article-title><source>Science</source><year>2002</year><volume>298</volume><fpage>1395</fpage><lpage>1401</lpage><pub-id pub-id-type="pmid">12376594</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villoslada</surname><given-names>P</given-names></name><name><surname>Abel</surname><given-names>K</given-names></name><name><surname>Heald</surname><given-names>N</given-names></name><name><surname>Goertsches</surname><given-names>R</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name><name><surname>Genain</surname><given-names>CP</given-names></name></person-group><article-title>Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>2942</fpage><lpage>2950</lpage><pub-id pub-id-type="pmid">11592070</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiller</surname><given-names>T</given-names></name><name><surname>Tsuiji</surname><given-names>M</given-names></name><name><surname>Yurasov</surname><given-names>S</given-names></name><name><surname>Velinzon</surname><given-names>K</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name></person-group><article-title>Autoreactivity in human IgG+ memory B cells</article-title><source>Immunity</source><year>2007</year><volume>26</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">17306569</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koelsch</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Duty</surname><given-names>A</given-names></name><name><surname>Helms</surname><given-names>C</given-names></name><name><surname>Mathias</surname><given-names>MD</given-names></name><name><surname>Jared</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Capra</surname><given-names>JD</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><article-title>Mature B cells class switched to IgD are autoreactive in healthy individuals</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>1558</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">17510706</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>Dinkelmann</surname><given-names>M</given-names></name><name><surname>Kimmig</surname><given-names>M</given-names></name><name><surname>Herkel</surname><given-names>J</given-names></name><name><surname>Meyer zum Buschenfelde</surname><given-names>KH</given-names></name></person-group><article-title>Estimation of the frequency of self-reactive T cells in health and inflammatory diseases by limiting dilution analysis and single cell cloning</article-title><source>J Autoimmun</source><year>1996</year><volume>9</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">8933283</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fredrikson</surname><given-names>S</given-names></name><name><surname>Soderstrom</surname><given-names>M</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>JB</given-names></name><name><surname>Kall</surname><given-names>TB</given-names></name><name><surname>Link</surname><given-names>H</given-names></name></person-group><article-title>Multiple sclerosis: occurrence of myelin basic protein peptide-reactive T cells in healthy family members</article-title><source>Acta Neurol Scand</source><year>1994</year><volume>89</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">7518178</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>T</given-names></name><name><surname>Takemori</surname><given-names>T</given-names></name></person-group><article-title>Selective roles of thymus-derived lymphocytes in the antibody response. I. Differential suppressive effect of carrier-primed T cells on hapten-specific IgM and IgG antibody responses</article-title><source>J Exp Med</source><year>1974</year><volume>140</volume><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">4134784</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name></person-group><article-title>Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>1151</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">7636184</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roncarolo</surname><given-names>MG</given-names></name><name><surname>Bacchetta</surname><given-names>R</given-names></name><name><surname>Bordignon</surname><given-names>C</given-names></name><name><surname>Narula</surname><given-names>S</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name></person-group><article-title>Type 1 T regulatory cells</article-title><source>Immunol Rev</source><year>2001</year><volume>182</volume><fpage>68</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11722624</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levings</surname><given-names>MK</given-names></name><name><surname>Gregori</surname><given-names>S</given-names></name><name><surname>Tresoldi</surname><given-names>E</given-names></name><name><surname>Cazzaniga</surname><given-names>S</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Roncarolo</surname><given-names>MG</given-names></name></person-group><article-title>Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>1162</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">15479730</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cottrez</surname><given-names>F</given-names></name><name><surname>Groux</surname><given-names>H</given-names></name></person-group><article-title>Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells</article-title><source>Transplantation</source><year>2004</year><volume>77</volume><fpage>S12</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">14726762</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><article-title>Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells</article-title><source>Microbes Infect</source><year>2001</year><volume>3</volume><fpage>947</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">11564443</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>RY</given-names></name><name><surname>Ansari</surname><given-names>AA</given-names></name><name><surname>Lian</surname><given-names>ZX</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name></person-group><article-title>Regulatory T cells: development, function and role in autoimmunity</article-title><source>Autoimmun Rev</source><year>2005</year><volume>4</volume><fpage>351</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">16081026</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><article-title>Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells</article-title><source>Immunol Rev</source><year>2001</year><volume>182</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">11722636</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>SG</given-names></name><name><surname>Gray</surname><given-names>JD</given-names></name><name><surname>Ohtsuka</surname><given-names>K</given-names></name><name><surname>Yamagiwa</surname><given-names>S</given-names></name><name><surname>Horwitz</surname><given-names>DA</given-names></name></person-group><article-title>Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>4183</fpage><lpage>4189</lpage><pub-id pub-id-type="pmid">12370347</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>B</given-names></name><name><surname>Mason</surname><given-names>D</given-names></name></person-group><article-title>The third function of the thymus</article-title><source>Immunol Today</source><year>2000</year><volume>21</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">10652468</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cupedo</surname><given-names>T</given-names></name><name><surname>Nagasawa</surname><given-names>M</given-names></name><name><surname>Weijer</surname><given-names>K</given-names></name><name><surname>Blom</surname><given-names>B</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><article-title>Development and activation of regulatory T cells in the human fetus</article-title><source>Eur J Immunol</source><year>2005</year><volume>35</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">15682453</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Kitawaki</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Onodera</surname><given-names>M</given-names></name><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells</article-title><source>Int Immunol</source><year>2004</year><volume>16</volume><fpage>1643</fpage><lpage>1656</lpage><pub-id pub-id-type="pmid">15466453</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veldhoen</surname><given-names>M</given-names></name><name><surname>Hocking</surname><given-names>RJ</given-names></name><name><surname>Atkins</surname><given-names>CJ</given-names></name><name><surname>Locksley</surname><given-names>RM</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name></person-group><article-title>TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells</article-title><source>Immunity</source><year>2006</year><volume>24</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">16473830</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bensinger</surname><given-names>SJ</given-names></name><name><surname>Bandeira</surname><given-names>A</given-names></name><name><surname>Jordan</surname><given-names>MS</given-names></name><name><surname>Caton</surname><given-names>AJ</given-names></name><name><surname>Laufer</surname><given-names>TM</given-names></name></person-group><article-title>Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells</article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>427</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">11514600</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>K</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Sandstrom</surname><given-names>K</given-names></name><name><surname>Lundin</surname><given-names>SB</given-names></name><name><surname>Suri-Payer</surname><given-names>E</given-names></name><name><surname>Rudin</surname><given-names>A</given-names></name></person-group><article-title>CD4+ CD25+ FOXP3+ regulatory T cells from human thymus and cord blood suppress antigen-specific T cell responses</article-title><source>Immunology</source><year>2005</year><volume>115</volume><fpage>516</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">16011520</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">15785760</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Boehmer</surname><given-names>H</given-names></name></person-group><article-title>Mechanisms of suppression by suppressor T cells</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">15785759</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Picca</surname><given-names>CC</given-names></name><name><surname>Caton</surname><given-names>AJ</given-names></name></person-group><article-title>The role of self-peptides in the development of CD4+ CD25+ regulatory T cells</article-title><source>Curr Opin Immunol</source><year>2005</year><volume>17</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">15766671</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fontenot</surname><given-names>JD</given-names></name><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><article-title>Foxp3 programs the development and function of CD4+CD25+ regulatory T cells</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">12612578</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Control of regulatory T cell development by the transcription factor Foxp3</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>1057</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">12522256</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khattri</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>T</given-names></name><name><surname>Yasayko</surname><given-names>SA</given-names></name><name><surname>Ramsdell</surname><given-names>F</given-names></name></person-group><article-title>An essential role for Scurfin in CD4+CD25+ T regulatory cells</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">12612581</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>JA</given-names></name><name><surname>Feuerer</surname><given-names>M</given-names></name><name><surname>Tash</surname><given-names>K</given-names></name><name><surname>Haxhinasto</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>J</given-names></name><name><surname>Melamed</surname><given-names>R</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name></person-group><article-title>Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature</article-title><source>Immunity</source><year>2007</year><volume>27</volume><fpage>786</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">18024188</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CS</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Tyznik</surname><given-names>AJ</given-names></name><name><surname>Self</surname><given-names>SG</given-names></name><name><surname>Liggitt</surname><given-names>D</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><article-title>Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors</article-title><source>Immunity</source><year>2004</year><volume>21</volume><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">15308106</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Clarke</surname><given-names>SR</given-names></name><name><surname>Negrou</surname><given-names>E</given-names></name><name><surname>Gallegos</surname><given-names>A</given-names></name><name><surname>Rudensky</surname><given-names>A</given-names></name></person-group><article-title>Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11740498</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisson</surname><given-names>S</given-names></name><name><surname>Darrasse-Jeze</surname><given-names>G</given-names></name><name><surname>Litvinova</surname><given-names>E</given-names></name><name><surname>Septier</surname><given-names>F</given-names></name><name><surname>Klatzmann</surname><given-names>D</given-names></name><name><surname>Liblau</surname><given-names>R</given-names></name><name><surname>Salomon</surname><given-names>BL</given-names></name></person-group><article-title>Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state</article-title><source>J Exp Med</source><year>2003</year><volume>198</volume><fpage>737</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">12939344</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allsopp</surname><given-names>RC</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Kashefi-Aazam</surname><given-names>M</given-names></name><name><surname>Rogaev</surname><given-names>EI</given-names></name><name><surname>Piatyszek</surname><given-names>MA</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Harley</surname><given-names>CB</given-names></name></person-group><article-title>Telomere shortening is associated with cell division in vitro and in vivo</article-title><source>Exp Cell Res</source><year>1995</year><volume>220</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">7664836</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>BH</given-names></name><name><surname>Ellis</surname><given-names>TM</given-names></name><name><surname>Peace</surname><given-names>DJ</given-names></name><name><surname>Diaz</surname><given-names>MO</given-names></name></person-group><article-title>Changes in telomerase activity and telomere length during human T lymphocyte senescence</article-title><source>Exp Cell Res</source><year>1997</year><volume>231</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">9087176</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gregg</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Clark</surname><given-names>FJ</given-names></name><name><surname>Dunnion</surname><given-names>D</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Chakraverty</surname><given-names>R</given-names></name><name><surname>Nayak</surname><given-names>L</given-names></name><name><surname>Moss</surname><given-names>PA</given-names></name></person-group><article-title>The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age</article-title><source>Clin Exp Immunol</source><year>2005</year><volume>140</volume><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">15932517</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mays</surname><given-names>LE</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group><article-title>Maintaining immunological tolerance with Foxp3</article-title><source>Cell Res</source><year>2007</year><volume>17</volume><fpage>904</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">17923863</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Hardegen</surname><given-names>N</given-names></name><name><surname>Lei</surname><given-names>KJ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Marinos</surname><given-names>N</given-names></name><name><surname>McGrady</surname><given-names>G</given-names></name><name><surname>Wahl</surname><given-names>SM</given-names></name></person-group><article-title>Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3</article-title><source>J Exp Med</source><year>2003</year><volume>198</volume><fpage>1875</fpage><lpage>1886</lpage><pub-id pub-id-type="pmid">14676299</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>MC</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Monteleone</surname><given-names>G</given-names></name><name><surname>Pallone</surname><given-names>F</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Neurath</surname><given-names>MF</given-names></name></person-group><article-title>Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>5149</fpage><lpage>5153</lpage><pub-id pub-id-type="pmid">15100250</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Laouar</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>MO</given-names></name><name><surname>Green</surname><given-names>EA</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><article-title>TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>4572</fpage><lpage>4577</lpage><pub-id pub-id-type="pmid">15070759</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selvaraj</surname><given-names>RK</given-names></name><name><surname>Geiger</surname><given-names>TL</given-names></name></person-group><article-title>A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>11</fpage><comment>following 1390</comment><pub-id pub-id-type="pmid">17695668</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>JZ</given-names></name></person-group><article-title>Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>2434</fpage><lpage>2441</lpage><pub-id pub-id-type="pmid">16906223</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Carson</surname><given-names>BD</given-names></name><name><surname>Nepom</surname><given-names>GT</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Buckner</surname><given-names>JH</given-names></name></person-group><article-title>De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>4103</fpage><lpage>4108</lpage><pub-id pub-id-type="pmid">15753318</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Kasprowicz</surname><given-names>DJ</given-names></name><name><surname>Gersuk</surname><given-names>VH</given-names></name><name><surname>Benard</surname><given-names>A</given-names></name><name><surname>Van Landeghen</surname><given-names>M</given-names></name><name><surname>Buckner</surname><given-names>JH</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name></person-group><article-title>Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><fpage>1437</fpage><lpage>1443</lpage><pub-id pub-id-type="pmid">14597769</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skapenko</surname><given-names>A</given-names></name><name><surname>Kalden</surname><given-names>JR</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name><name><surname>Schulze-Koops</surname><given-names>H</given-names></name></person-group><article-title>The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>6107</fpage><lpage>6116</lpage><pub-id pub-id-type="pmid">16237107</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grimbert</surname><given-names>P</given-names></name><name><surname>Bouguermouh</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>N</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Allakhverdi</surname><given-names>Z</given-names></name><name><surname>Braun</surname><given-names>D</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Rubio</surname><given-names>M</given-names></name><name><surname>Delespesse</surname><given-names>G</given-names></name><name><surname>Sarfati</surname><given-names>M</given-names></name></person-group><article-title>Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation</article-title><source>J Immunol</source><year>2006</year><volume>177</volume><fpage>3534</fpage><lpage>3541</lpage><pub-id pub-id-type="pmid">16951312</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Apostolou</surname><given-names>I</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name></person-group><article-title>In vivo instruction of suppressor commitment in naive T cells</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>1401</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">15148338</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knoechel</surname><given-names>B</given-names></name><name><surname>Lohr</surname><given-names>J</given-names></name><name><surname>Kahn</surname><given-names>E</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Abbas</surname><given-names>AK</given-names></name></person-group><article-title>Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen</article-title><source>J Exp Med</source><year>2005</year><volume>202</volume><fpage>1375</fpage><lpage>1386</lpage><pub-id pub-id-type="pmid">16287710</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kretschmer</surname><given-names>K</given-names></name><name><surname>Apostolou</surname><given-names>I</given-names></name><name><surname>Hawiger</surname><given-names>D</given-names></name><name><surname>Khazaie</surname><given-names>K</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name></person-group><article-title>Inducing and expanding regulatory T cell populations by foreign antigen</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>1219</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">16244650</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curotto de Lafaille</surname><given-names>MA</given-names></name><name><surname>Lino</surname><given-names>AC</given-names></name><name><surname>Kutchukhidze</surname><given-names>N</given-names></name><name><surname>Lafaille</surname><given-names>JJ</given-names></name></person-group><article-title>CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>7259</fpage><lpage>7268</lpage><pub-id pub-id-type="pmid">15585848</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorstenson</surname><given-names>KM</given-names></name><name><surname>Khoruts</surname><given-names>A</given-names></name></person-group><article-title>Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">11418648</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>SE</given-names></name><name><surname>Passerini</surname><given-names>L</given-names></name><name><surname>Bacchetta</surname><given-names>R</given-names></name><name><surname>Crellin</surname><given-names>N</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Orban</surname><given-names>PC</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Roncarolo</surname><given-names>MG</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name></person-group><article-title>The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>3276</fpage><lpage>3284</lpage><pub-id pub-id-type="pmid">16211090</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Houston</surname><given-names>E</given-names></name><name><surname>DeRoos</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>WY</given-names></name><name><surname>Stray-Pedersen</surname><given-names>A</given-names></name><name><surname>Ocheltree</surname><given-names>EL</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><article-title>Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>6659</fpage><lpage>6664</lpage><pub-id pub-id-type="pmid">16617117</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Putnam</surname><given-names>AL</given-names></name><name><surname>Xu-Yu</surname><given-names>Z</given-names></name><name><surname>Szot</surname><given-names>GL</given-names></name><name><surname>Lee</surname><given-names>MR</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>PA</given-names></name><name><surname>Kapranov</surname><given-names>P</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name><name><surname>Fazekas de St Groth</surname><given-names>B</given-names></name><name><surname>Clayberger</surname><given-names>C</given-names></name><name><surname>Soper</surname><given-names>DM</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>1701</fpage><lpage>1711</lpage><pub-id pub-id-type="pmid">16818678</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seddiki</surname><given-names>N</given-names></name><name><surname>Santner-Nanan</surname><given-names>B</given-names></name><name><surname>Martinson</surname><given-names>J</given-names></name><name><surname>Zaunders</surname><given-names>J</given-names></name><name><surname>Sasson</surname><given-names>S</given-names></name><name><surname>Landay</surname><given-names>A</given-names></name><name><surname>Solomon</surname><given-names>M</given-names></name><name><surname>Selby</surname><given-names>W</given-names></name><name><surname>Alexander</surname><given-names>SI</given-names></name><name><surname>Nanan</surname><given-names>R</given-names></name><name><surname>Kelleher</surname><given-names>A</given-names></name><name><surname>Fazekas de St Groth</surname><given-names>B</given-names></name></person-group><article-title>Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>1693</fpage><lpage>1700</lpage><pub-id pub-id-type="pmid">16818676</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>FL</given-names></name><name><surname>Zhu</surname><given-names>LP</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group><article-title>Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus</article-title><source>Ann Rheum Dis</source><year>2008</year><volume>67</volume><fpage>1037</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">18199598</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>H</given-names></name><name><surname>Zhen</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells</article-title><source>Cell Mol Immunol</source><year>2006</year><volume>3</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">16893499</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><article-title>Regulatory T-cell compartmentalization and trafficking</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">16537800</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Evdemon-Hogan</surname><given-names>M</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>Lackner</surname><given-names>A</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">15322536</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>CD4+CD25high regulatory cells in human peripheral blood</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>1245</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">11466340</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamdy</surname><given-names>AF</given-names></name><name><surname>Bakr</surname><given-names>MA</given-names></name><name><surname>Ghoneim</surname><given-names>MA</given-names></name></person-group><article-title>Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>1225</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">18337483</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>MA</given-names></name><name><surname>Trotter</surname><given-names>JF</given-names></name><name><surname>Wachs</surname><given-names>M</given-names></name><name><surname>Bak</surname><given-names>T</given-names></name><name><surname>Campsen</surname><given-names>J</given-names></name><name><surname>Skibba</surname><given-names>A</given-names></name><name><surname>Kam</surname><given-names>I</given-names></name></person-group><article-title>Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma</article-title><source>Liver Transpl</source><year>2008</year><volume>14</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">18324656</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez-Simon</surname><given-names>JA</given-names></name><name><surname>Sanchez-Abarca</surname><given-names>I</given-names></name><name><surname>Diez-Campelo</surname><given-names>M</given-names></name><name><surname>Caballero</surname><given-names>D</given-names></name><name><surname>San Miguel</surname><given-names>J</given-names></name></person-group><article-title>Chronic graft-versus-host disease: Pathogenesis and clinical management</article-title><source>Drugs</source><year>2006</year><volume>66</volume><fpage>1041</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">16789791</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>RT</given-names></name><name><surname>Wiederrecht</surname><given-names>GJ</given-names></name></person-group><article-title>Immunopharmacology of rapamycin</article-title><source>Annu Rev Immunol</source><year>1996</year><volume>14</volume><fpage>483</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">8717522</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>L</given-names></name><name><surname>Whiteside</surname><given-names>TL</given-names></name><name><surname>Knights</surname><given-names>A</given-names></name><name><surname>Bergmann</surname><given-names>C</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>Zippelius</surname><given-names>A</given-names></name></person-group><article-title>Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">17182569</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keever-Taylor</surname><given-names>CA</given-names></name><name><surname>Browning</surname><given-names>MB</given-names></name><name><surname>Johnson</surname><given-names>BD</given-names></name><name><surname>Truitt</surname><given-names>RL</given-names></name><name><surname>Bredeson</surname><given-names>CN</given-names></name><name><surname>Behn</surname><given-names>B</given-names></name><name><surname>Tsao</surname><given-names>A</given-names></name></person-group><article-title>Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis</article-title><source>Cytotherapy</source><year>2007</year><volume>9</volume><fpage>144</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">17453966</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turka</surname><given-names>LA</given-names></name><name><surname>Walsh</surname><given-names>PT</given-names></name></person-group><article-title>IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>1440</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">17981641</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hombach</surname><given-names>AA</given-names></name><name><surname>Kofler</surname><given-names>D</given-names></name><name><surname>Hombach</surname><given-names>A</given-names></name><name><surname>Rappl</surname><given-names>G</given-names></name><name><surname>Abken</surname><given-names>H</given-names></name></person-group><article-title>Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>7924</fpage><lpage>7931</lpage><pub-id pub-id-type="pmid">18025240</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oberg</surname><given-names>HH</given-names></name><name><surname>Wesch</surname><given-names>D</given-names></name><name><surname>Lenke</surname><given-names>J</given-names></name><name><surname>Kabelitz</surname><given-names>D</given-names></name></person-group><article-title>An optimized method for the functional analysis of human regulatory T cells</article-title><source>Scand J Immunol</source><year>2006</year><volume>64</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">16918705</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JS</given-names></name><name><surname>Krishnadas</surname><given-names>DK</given-names></name><name><surname>Agrawal</surname><given-names>B</given-names></name></person-group><article-title>Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood</article-title><source>Int Immunol</source><year>2007</year><volume>19</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">17289657</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fehervari</surname><given-names>Z</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>CD4+ Tregs and immune control</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>1209</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">15520849</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Annunziato</surname><given-names>F</given-names></name><name><surname>Cosmi</surname><given-names>L</given-names></name><name><surname>Liotta</surname><given-names>F</given-names></name><name><surname>Lazzeri</surname><given-names>E</given-names></name><name><surname>Manetti</surname><given-names>R</given-names></name><name><surname>Vanini</surname><given-names>V</given-names></name><name><surname>Romagnani</surname><given-names>P</given-names></name><name><surname>Maggi</surname><given-names>E</given-names></name><name><surname>Romagnani</surname><given-names>S</given-names></name></person-group><article-title>Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes</article-title><source>J Exp Med</source><year>2002</year><volume>196</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">12163566</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonuleit</surname><given-names>H</given-names></name><name><surname>Schmitt</surname><given-names>E</given-names></name><name><surname>Kakirman</surname><given-names>H</given-names></name><name><surname>Stassen</surname><given-names>M</given-names></name><name><surname>Knop</surname><given-names>J</given-names></name><name><surname>Enk</surname><given-names>AH</given-names></name></person-group><article-title>Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells</article-title><source>J Exp Med</source><year>2002</year><volume>196</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">12119350</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Kuniyasu</surname><given-names>Y</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>J</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state</article-title><source>Int Immunol</source><year>1998</year><volume>10</volume><fpage>1969</fpage><lpage>1980</lpage><pub-id pub-id-type="pmid">9885918</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de la Rosa</surname><given-names>M</given-names></name><name><surname>Rutz</surname><given-names>S</given-names></name><name><surname>Dorninger</surname><given-names>H</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-2 is essential for CD4+CD25+ regulatory T cell function</article-title><source>Eur J Immunol</source><year>2004</year><volume>34</volume><fpage>2480</fpage><lpage>2488</lpage><pub-id pub-id-type="pmid">15307180</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Boden</surname><given-names>EK</given-names></name><name><surname>Henriksen</surname><given-names>KJ</given-names></name><name><surname>Bour-Jordan</surname><given-names>H</given-names></name><name><surname>Bi</surname><given-names>M</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function</article-title><source>Eur J Immunol</source><year>2004</year><volume>34</volume><fpage>2996</fpage><lpage>3005</lpage><pub-id pub-id-type="pmid">15468055</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>S</given-names></name><name><surname>Greenwald</surname><given-names>R</given-names></name><name><surname>Izcue</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>N</given-names></name><name><surname>Mandelbrot</surname><given-names>D</given-names></name><name><surname>Francisco</surname><given-names>L</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name></person-group><article-title>Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo</article-title><source>J Immunol</source><year>2006</year><volume>177</volume><fpage>4376</fpage><lpage>4383</lpage><pub-id pub-id-type="pmid">16982872</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paust</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>McCarty</surname><given-names>N</given-names></name><name><surname>Cantor</surname><given-names>H</given-names></name></person-group><article-title>Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>10398</fpage><lpage>10403</lpage><pub-id pub-id-type="pmid">15235129</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Wahl</surname><given-names>SM</given-names></name></person-group><article-title>Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>1849</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">9815262</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fallarino</surname><given-names>F</given-names></name><name><surname>Grohmann</surname><given-names>U</given-names></name><name><surname>Hwang</surname><given-names>KW</given-names></name><name><surname>Orabona</surname><given-names>C</given-names></name><name><surname>Vacca</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>R</given-names></name><name><surname>Belladonna</surname><given-names>ML</given-names></name><name><surname>Fioretti</surname><given-names>MC</given-names></name><name><surname>Alegre</surname><given-names>ML</given-names></name><name><surname>Puccetti</surname><given-names>P</given-names></name></person-group><article-title>Modulation of tryptophan catabolism by regulatory T cells</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><fpage>1206</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">14578884</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stassen</surname><given-names>M</given-names></name><name><surname>Fondel</surname><given-names>S</given-names></name><name><surname>Bopp</surname><given-names>T</given-names></name><name><surname>Richter</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Kubach</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Knop</surname><given-names>J</given-names></name><name><surname>Enk</surname><given-names>AH</given-names></name><name><surname>Schmitt</surname><given-names>S</given-names></name><name><surname>Schmitt</surname><given-names>E</given-names></name><name><surname>Jonuleit</surname><given-names>H</given-names></name></person-group><article-title>Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells</article-title><source>Eur J Immunol</source><year>2004</year><volume>34</volume><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="pmid">15114663</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raghavan</surname><given-names>S</given-names></name><name><surname>Suri-Payer</surname><given-names>E</given-names></name><name><surname>Holmgren</surname><given-names>J</given-names></name></person-group><article-title>Antigen-specific in vitro suppression of murine Helicobacter pylori-reactive immunopathological T cells by CD4CD25 regulatory T cells</article-title><source>Scand J Immunol</source><year>2004</year><volume>60</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">15238076</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BD</given-names></name><name><surname>Jing</surname><given-names>W</given-names></name><name><surname>Orentas</surname><given-names>RJ</given-names></name></person-group><article-title>CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma</article-title><source>J Immunother</source><year>2007</year><volume>30</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">17471167</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Leventhal</surname><given-names>JR</given-names></name></person-group><article-title>Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells</article-title><source>Transplantation</source><year>2006</year><volume>82</volume><fpage>1749</fpage><lpage>1755</lpage><pub-id pub-id-type="pmid">17198271</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cosmi</surname><given-names>L</given-names></name><name><surname>Liotta</surname><given-names>F</given-names></name><name><surname>Angeli</surname><given-names>R</given-names></name><name><surname>Mazzinghi</surname><given-names>B</given-names></name><name><surname>Santarlasci</surname><given-names>V</given-names></name><name><surname>Manetti</surname><given-names>R</given-names></name><name><surname>Lasagni</surname><given-names>L</given-names></name><name><surname>Vanini</surname><given-names>V</given-names></name><name><surname>Romagnani</surname><given-names>P</given-names></name><name><surname>Maggi</surname><given-names>E</given-names></name><name><surname>Annunziato</surname><given-names>F</given-names></name><name><surname>Romagnani</surname><given-names>S</given-names></name></person-group><article-title>Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>3117</fpage><lpage>3121</lpage><pub-id pub-id-type="pmid">15070693</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bopp</surname><given-names>T</given-names></name><name><surname>Palmetshofer</surname><given-names>A</given-names></name><name><surname>Serfling</surname><given-names>E</given-names></name><name><surname>Heib</surname><given-names>V</given-names></name><name><surname>Schmitt</surname><given-names>S</given-names></name><name><surname>Richter</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Schild</surname><given-names>H</given-names></name><name><surname>Schmitt</surname><given-names>E</given-names></name><name><surname>Stassen</surname><given-names>M</given-names></name></person-group><article-title>NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells</article-title><source>J Exp Med</source><year>2005</year><volume>201</volume><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">15657288</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suto</surname><given-names>A</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Kagami</surname><given-names>SI</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Iwamoto</surname><given-names>I</given-names></name></person-group><article-title>Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>680</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">11520737</pub-id></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dieckmann</surname><given-names>D</given-names></name><name><surname>Bruett</surname><given-names>CH</given-names></name><name><surname>Ploettner</surname><given-names>H</given-names></name><name><surname>Lutz</surname><given-names>MB</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name></person-group><article-title>Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]</article-title><source>J Exp Med</source><year>2002</year><volume>196</volume><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">12119349</pub-id></citation></ref><ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dieckmann</surname><given-names>D</given-names></name><name><surname>Plottner</surname><given-names>H</given-names></name><name><surname>Berchtold</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>T</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name></person-group><article-title>Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">11390437</pub-id></citation></ref><ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>VL</given-names></name><name><surname>Wilkinson</surname><given-names>JE</given-names></name><name><surname>Russell</surname><given-names>LB</given-names></name></person-group><article-title>X-linked lymphoreticular disease in the scurfy (sf) mutant mouse</article-title><source>Am J Pathol</source><year>1991</year><volume>138</volume><fpage>1379</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">2053595</pub-id></citation></ref><ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyk-Pearson</surname><given-names>SK</given-names></name><name><surname>Bakke</surname><given-names>AC</given-names></name><name><surname>Held</surname><given-names>PK</given-names></name><name><surname>Wildin</surname><given-names>RS</given-names></name></person-group><article-title>Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes</article-title><source>Clin Exp Immunol</source><year>2003</year><volume>133</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">12869024</pub-id></citation></ref><ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>KE</given-names></name><name><surname>McDonald-McGinn</surname><given-names>D</given-names></name><name><surname>Zackai</surname><given-names>EH</given-names></name></person-group><article-title>CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia</article-title><source>Clin Diagn Lab Immunol</source><year>2002</year><volume>9</volume><fpage>1129</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">12204972</pub-id></citation></ref><ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Kuniyasu</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>J</given-names></name><name><surname>Otsuka</surname><given-names>F</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>5317</fpage><lpage>5326</lpage><pub-id pub-id-type="pmid">10228007</pub-id></citation></ref><ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>387</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">8760792</pub-id></citation></ref><ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gambineri</surname><given-names>E</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name></person-group><article-title>Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis</article-title><source>Curr Opin Rheumatol</source><year>2003</year><volume>15</volume><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">12819471</pub-id></citation></ref><ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>CL</given-names></name><name><surname>Christie</surname><given-names>J</given-names></name><name><surname>Ramsdell</surname><given-names>F</given-names></name><name><surname>Brunkow</surname><given-names>ME</given-names></name><name><surname>Ferguson</surname><given-names>PJ</given-names></name><name><surname>Whitesell</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>TE</given-names></name><name><surname>Saulsbury</surname><given-names>FT</given-names></name><name><surname>Chance</surname><given-names>PF</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name></person-group><article-title>The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3</article-title><source>Nat Genet</source><year>2001</year><volume>27</volume><fpage>20</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11137993</pub-id></citation></ref><ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bacchetta</surname><given-names>R</given-names></name><name><surname>Passerini</surname><given-names>L</given-names></name><name><surname>Gambineri</surname><given-names>E</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Allan</surname><given-names>SE</given-names></name><name><surname>Perroni</surname><given-names>L</given-names></name><name><surname>Dagna-Bricarelli</surname><given-names>F</given-names></name><name><surname>Sartirana</surname><given-names>C</given-names></name><name><surname>Matthes-Martin</surname><given-names>S</given-names></name><name><surname>Lawitschka</surname><given-names>A</given-names></name><name><surname>Azzari</surname><given-names>C</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name><name><surname>Roncarolo</surname><given-names>MG</given-names></name></person-group><article-title>Defective regulatory and effector T cell functions in patients with FOXP3 mutations</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1713</fpage><lpage>1722</lpage><pub-id pub-id-type="pmid">16741580</pub-id></citation></ref><ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Sinclair</surname><given-names>J</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Cale</surname><given-names>CM</given-names></name><name><surname>Murch</surname><given-names>S</given-names></name><name><surname>Perroni</surname><given-names>L</given-names></name><name><surname>Davies</surname><given-names>G</given-names></name><name><surname>Amrolia</surname><given-names>P</given-names></name><name><surname>Qasim</surname><given-names>W</given-names></name></person-group><article-title>Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome</article-title><source>Pediatrics</source><year>2008</year><volume>121</volume><fpage>e998</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">18316354</pub-id></citation></ref><ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wildin</surname><given-names>RS</given-names></name><name><surname>Smyk-Pearson</surname><given-names>S</given-names></name><name><surname>Filipovich</surname><given-names>AH</given-names></name></person-group><article-title>Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome</article-title><source>J Med Genet</source><year>2002</year><volume>39</volume><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">12161590</pub-id></citation></ref><ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viglietta</surname><given-names>V</given-names></name><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>971</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">15067033</pub-id></citation></ref><ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Putnam</surname><given-names>AL</given-names></name><name><surname>Vendrame</surname><given-names>F</given-names></name><name><surname>Dotta</surname><given-names>F</given-names></name><name><surname>Gottlieb</surname><given-names>PA</given-names></name></person-group><article-title>CD4+CD25high regulatory T cells in human autoimmune diabetes</article-title><source>J Autoimmun</source><year>2005</year><volume>24</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15725577</pub-id></citation></ref><ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brusko</surname><given-names>T</given-names></name><name><surname>Atkinson</surname><given-names>M</given-names></name></person-group><article-title>Treg in type 1 diabetes</article-title><source>Cell Biochem Biophys</source><year>2007</year><volume>48</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">17709886</pub-id></citation></ref><ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brusko</surname><given-names>T</given-names></name><name><surname>Wasserfall</surname><given-names>C</given-names></name><name><surname>McGrail</surname><given-names>K</given-names></name><name><surname>Schatz</surname><given-names>R</given-names></name><name><surname>Viener</surname><given-names>HL</given-names></name><name><surname>Schatz</surname><given-names>D</given-names></name><name><surname>Haller</surname><given-names>M</given-names></name><name><surname>Rockell</surname><given-names>J</given-names></name><name><surname>Gottlieb</surname><given-names>P</given-names></name><name><surname>Clare-Salzler</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>M</given-names></name></person-group><article-title>No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>604</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">17327427</pub-id></citation></ref><ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brusko</surname><given-names>TM</given-names></name><name><surname>Wasserfall</surname><given-names>CH</given-names></name><name><surname>Clare-Salzler</surname><given-names>MJ</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Atkinson</surname><given-names>MA</given-names></name></person-group><article-title>Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>1407</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">15855327</pub-id></citation></ref><ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kukreja</surname><given-names>A</given-names></name><name><surname>Cost</surname><given-names>G</given-names></name><name><surname>Marker</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Lin-Su</surname><given-names>K</given-names></name><name><surname>Ten</surname><given-names>S</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name><name><surname>Exley</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>B</given-names></name><name><surname>Porcelli</surname><given-names>S</given-names></name><name><surname>Maclaren</surname><given-names>N</given-names></name></person-group><article-title>Multiple immuno-regulatory defects in type-1 diabetes</article-title><source>J Clin Invest</source><year>2002</year><volume>109</volume><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">11781358</pub-id></citation></ref><ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Kleer</surname><given-names>IM</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Varsani</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>de Jager</surname><given-names>W</given-names></name><name><surname>Pugayung</surname><given-names>G</given-names></name><name><surname>Giannoni</surname><given-names>F</given-names></name><name><surname>Rijkers</surname><given-names>G</given-names></name><name><surname>Albani</surname><given-names>S</given-names></name><name><surname>Kuis</surname><given-names>W</given-names></name><name><surname>Prakken</surname><given-names>B</given-names></name></person-group><article-title>CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>6435</fpage><lpage>6443</lpage><pub-id pub-id-type="pmid">15128835</pub-id></citation></ref><ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasare</surname><given-names>C</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>1033</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">12532024</pub-id></citation></ref><ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Malmstrom</surname><given-names>V</given-names></name><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Hafler</surname><given-names>D</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Trollmo</surname><given-names>C</given-names></name></person-group><article-title>Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis</article-title><source>Eur J Immunol</source><year>2003</year><volume>33</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">12594850</pub-id></citation></ref><ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massa</surname><given-names>M</given-names></name><name><surname>Passalia</surname><given-names>M</given-names></name><name><surname>Manzoni</surname><given-names>SM</given-names></name><name><surname>Campanelli</surname><given-names>R</given-names></name><name><surname>Ciardelli</surname><given-names>L</given-names></name><name><surname>Yung</surname><given-names>GP</given-names></name><name><surname>Kamphuis</surname><given-names>S</given-names></name><name><surname>Pistorio</surname><given-names>A</given-names></name><name><surname>Meli</surname><given-names>V</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Prakken</surname><given-names>B</given-names></name><name><surname>Martini</surname><given-names>A</given-names></name><name><surname>Albani</surname><given-names>S</given-names></name></person-group><article-title>Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis</article-title><source>Arthritis Rheum</source><year>2007</year><volume>56</volume><fpage>1648</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">17469159</pub-id></citation></ref><ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Kleer</surname><given-names>I</given-names></name><name><surname>Vastert</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Teklenburg</surname><given-names>G</given-names></name><name><surname>Arkesteijn</surname><given-names>G</given-names></name><name><surname>Yung</surname><given-names>GP</given-names></name><name><surname>Albani</surname><given-names>S</given-names></name><name><surname>Kuis</surname><given-names>W</given-names></name><name><surname>Wulffraat</surname><given-names>N</given-names></name><name><surname>Prakken</surname><given-names>B</given-names></name></person-group><article-title>Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>1696</fpage><lpage>1702</lpage><pub-id pub-id-type="pmid">16263787</pub-id></citation></ref><ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruprecht</surname><given-names>CR</given-names></name><name><surname>Gattorno</surname><given-names>M</given-names></name><name><surname>Ferlito</surname><given-names>F</given-names></name><name><surname>Gregorio</surname><given-names>A</given-names></name><name><surname>Martini</surname><given-names>A</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><article-title>Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia</article-title><source>J Exp Med</source><year>2005</year><volume>201</volume><fpage>1793</fpage><lpage>1803</lpage><pub-id pub-id-type="pmid">15939793</pub-id></citation></ref><ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duggleby</surname><given-names>RC</given-names></name><name><surname>Shaw</surname><given-names>TN</given-names></name><name><surname>Jarvis</surname><given-names>LB</given-names></name><name><surname>Kaur</surname><given-names>G</given-names></name><name><surname>Gaston</surname><given-names>JS</given-names></name></person-group><article-title>CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells</article-title><source>Immunology</source><year>2007</year><volume>121</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">17425604</pub-id></citation></ref><ref id="B113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>CR</given-names></name><name><surname>Fung</surname><given-names>LL</given-names></name><name><surname>Lin</surname><given-names>LH</given-names></name><name><surname>Tsai</surname><given-names>CN</given-names></name></person-group><article-title>The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis</article-title><source>Scand J Immunol</source><year>2005</year><volume>62</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">16179019</pub-id></citation></ref><ref id="B114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>van Vollenhoven</surname><given-names>R</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Trollmo</surname><given-names>C</given-names></name><name><surname>Malmstrom</surname><given-names>V</given-names></name></person-group><article-title>CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease</article-title><source>Arthritis Res Ther</source><year>2004</year><volume>6</volume><fpage>R335</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">15225369</pub-id></citation></ref><ref id="B115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dombrecht</surname><given-names>EJ</given-names></name><name><surname>Aerts</surname><given-names>NE</given-names></name><name><surname>Schuerwegh</surname><given-names>AJ</given-names></name><name><surname>Hagendorens</surname><given-names>MM</given-names></name><name><surname>Ebo</surname><given-names>DG</given-names></name><name><surname>Van Offel</surname><given-names>JF</given-names></name><name><surname>Bridts</surname><given-names>CH</given-names></name><name><surname>Stevens</surname><given-names>WJ</given-names></name><name><surname>De Clerck</surname><given-names>LS</given-names></name></person-group><article-title>Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>2006</year><volume>24</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16539816</pub-id></citation></ref><ref id="B116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Amelsfort</surname><given-names>JM</given-names></name><name><surname>Jacobs</surname><given-names>KM</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Lafeber</surname><given-names>FP</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name></person-group><article-title>CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>2775</fpage><lpage>2785</lpage><pub-id pub-id-type="pmid">15457445</pub-id></citation></ref><ref id="B117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehrenstein</surname><given-names>MR</given-names></name><name><surname>Evans</surname><given-names>JG</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Warnes</surname><given-names>G</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name><name><surname>Mauri</surname><given-names>C</given-names></name></person-group><article-title>Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy</article-title><source>J Exp Med</source><year>2004</year><volume>200</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">15280421</pub-id></citation></ref><ref id="B118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vigna-Perez</surname><given-names>M</given-names></name><name><surname>Abud-Mendoza</surname><given-names>C</given-names></name><name><surname>Portillo-Salazar</surname><given-names>H</given-names></name><name><surname>Alvarado-Sanchez</surname><given-names>B</given-names></name><name><surname>Cuevas-Orta</surname><given-names>E</given-names></name><name><surname>Moreno-Valdes</surname><given-names>R</given-names></name><name><surname>Baranda</surname><given-names>L</given-names></name><name><surname>Paredes-Saharopulos</surname><given-names>O</given-names></name><name><surname>Gonzalez-Amaro</surname><given-names>R</given-names></name></person-group><article-title>Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis</article-title><source>Clin Exp Immunol</source><year>2005</year><volume>141</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">15996202</pub-id></citation></ref><ref id="B119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mottonen</surname><given-names>M</given-names></name><name><surname>Heikkinen</surname><given-names>J</given-names></name><name><surname>Mustonen</surname><given-names>L</given-names></name><name><surname>Isomaki</surname><given-names>P</given-names></name><name><surname>Luukkainen</surname><given-names>R</given-names></name><name><surname>Lassila</surname><given-names>O</given-names></name></person-group><article-title>CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis</article-title><source>Clin Exp Immunol</source><year>2005</year><volume>140</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">15807863</pub-id></citation></ref><ref id="B120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jia</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis</article-title><source>Scand J Rheumatol</source><year>2007</year><volume>36</volume><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">18092263</pub-id></citation></ref><ref id="B121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>F</given-names></name><name><surname>Himsel</surname><given-names>A</given-names></name><name><surname>Rehart</surname><given-names>S</given-names></name><name><surname>Stanczyk</surname><given-names>J</given-names></name><name><surname>Beutel</surname><given-names>B</given-names></name><name><surname>Zimmermann</surname><given-names>SY</given-names></name><name><surname>Koehl</surname><given-names>U</given-names></name><name><surname>Moller</surname><given-names>B</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Kaltwasser</surname><given-names>JP</given-names></name><name><surname>Pfeilschifter</surname><given-names>JM</given-names></name><name><surname>Radeke</surname><given-names>HH</given-names></name></person-group><article-title>Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>1151</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">17392348</pub-id></citation></ref><ref id="B122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HY</given-names></name><name><surname>Staines</surname><given-names>NA</given-names></name></person-group><article-title>A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen</article-title><source>Lupus</source><year>2004</year><volume>13</volume><fpage>192</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15119549</pub-id></citation></ref><ref id="B123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubio</surname><given-names>CF</given-names></name><name><surname>Kench</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>DM</given-names></name><name><surname>Yawger</surname><given-names>R</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name></person-group><article-title>Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">8683157</pub-id></citation></ref><ref id="B124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fatenejad</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>SL</given-names></name><name><surname>Disorbo</surname><given-names>O</given-names></name><name><surname>Craft</surname><given-names>J</given-names></name></person-group><article-title>Central T cell tolerance in lupus-prone mice: influence of autoimmune background and the lpr mutation</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>6427</fpage><lpage>6432</lpage><pub-id pub-id-type="pmid">9834135</pub-id></citation></ref><ref id="B125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crispin</surname><given-names>JC</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Alcocer-Varela</surname><given-names>J</given-names></name></person-group><article-title>Quantification of regulatory T cells in patients with systemic lupus erythematosus</article-title><source>J Autoimmun</source><year>2003</year><volume>21</volume><fpage>273</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">14599852</pub-id></citation></ref><ref id="B126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>CR</given-names></name><name><surname>Fung</surname><given-names>LL</given-names></name><name><surname>Wu</surname><given-names>CR</given-names></name></person-group><article-title>Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus</article-title><source>Scand J Immunol</source><year>2004</year><volume>59</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">14871297</pub-id></citation></ref><ref id="B127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellor-Pita</surname><given-names>S</given-names></name><name><surname>Citores</surname><given-names>MJ</given-names></name><name><surname>Castejon</surname><given-names>R</given-names></name><name><surname>Tutor-Ureta</surname><given-names>P</given-names></name><name><surname>Yebra-Bango</surname><given-names>M</given-names></name><name><surname>Andreu</surname><given-names>JL</given-names></name><name><surname>Vargas</surname><given-names>JA</given-names></name></person-group><article-title>Decrease of regulatory T cells in patients with systemic lupus erythematosus</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>553</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">16531555</pub-id></citation></ref><ref id="B128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crispin</surname><given-names>JC</given-names></name><name><surname>Vargas</surname><given-names>MI</given-names></name><name><surname>Alcocer-Varela</surname><given-names>J</given-names></name></person-group><article-title>Immunoregulatory T cells in autoimmunity</article-title><source>Autoimmun Rev</source><year>2004</year><volume>3</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15003187</pub-id></citation></ref><ref id="B129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azab</surname><given-names>NA</given-names></name><name><surname>Bassyouni</surname><given-names>IH</given-names></name><name><surname>Emad</surname><given-names>Y</given-names></name><name><surname>Abd El-Wahab</surname><given-names>GA</given-names></name><name><surname>Hamdy</surname><given-names>G</given-names></name><name><surname>Mashahit</surname><given-names>MA</given-names></name></person-group><article-title>CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids</article-title><source>Clin Immunol</source><year>2008</year><volume>127</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">18299252</pub-id></citation></ref><ref id="B130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name><name><surname>Ling</surname><given-names>QD</given-names></name><name><surname>Chan</surname><given-names>CH</given-names></name></person-group><article-title>The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients</article-title><source>Eur J Clin Invest</source><year>2007</year><volume>37</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">18036033</pub-id></citation></ref><ref id="B131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cepika</surname><given-names>AM</given-names></name><name><surname>Marinic</surname><given-names>I</given-names></name><name><surname>Morovic-Vergles</surname><given-names>J</given-names></name><name><surname>Soldo-Juresa</surname><given-names>D</given-names></name><name><surname>Gagro</surname><given-names>A</given-names></name></person-group><article-title>Effect of steroids on the frequency of regulatory T cells and expression of FOXP3 in a patient with systemic lupus erythematosus: a two-year follow-up</article-title><source>Lupus</source><year>2007</year><volume>16</volume><fpage>374</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">17576742</pub-id></citation></ref><ref id="B132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valencia</surname><given-names>X</given-names></name><name><surname>Yarboro</surname><given-names>C</given-names></name><name><surname>Illei</surname><given-names>G</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group><article-title>Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>2579</fpage><lpage>2588</lpage><pub-id pub-id-type="pmid">17277168</pub-id></citation></ref><ref id="B133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>LC</given-names></name><name><surname>Lin</surname><given-names>YT</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>DT</given-names></name><name><surname>Chiang</surname><given-names>BL</given-names></name></person-group><article-title>Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus</article-title><source>Immunology</source><year>2006</year><volume>117</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">16423064</pub-id></citation></ref><ref id="B134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Kuang</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">18311820</pub-id></citation></ref><ref id="B135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barath</surname><given-names>S</given-names></name><name><surname>Soltesz</surname><given-names>P</given-names></name><name><surname>Kiss</surname><given-names>E</given-names></name><name><surname>Aleksza</surname><given-names>M</given-names></name><name><surname>Zeher</surname><given-names>M</given-names></name><name><surname>Szegedi</surname><given-names>G</given-names></name><name><surname>Sipka</surname><given-names>S</given-names></name></person-group><article-title>The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients</article-title><source>Autoimmunity</source><year>2007</year><volume>40</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">17966042</pub-id></citation></ref><ref id="B136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottenberg</surname><given-names>JE</given-names></name><name><surname>Lavie</surname><given-names>F</given-names></name><name><surname>Abbed</surname><given-names>K</given-names></name><name><surname>Gasnault</surname><given-names>J</given-names></name><name><surname>Le Nevot</surname><given-names>E</given-names></name><name><surname>Delfraissy</surname><given-names>JF</given-names></name><name><surname>Taoufik</surname><given-names>Y</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name></person-group><article-title>CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome</article-title><source>J Autoimmun</source><year>2005</year><volume>24</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">15848046</pub-id></citation></ref><ref id="B137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Harris</surname><given-names>DC</given-names></name></person-group><article-title>T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjogren's syndrome</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><fpage>2438</fpage><lpage>2445</lpage><pub-id pub-id-type="pmid">18050367</pub-id></citation></ref><ref id="B138"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuno</surname><given-names>K</given-names></name><name><surname>Yuge</surname><given-names>T</given-names></name><name><surname>Kusuhara</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>H</given-names></name><name><surname>Nishio</surname><given-names>H</given-names></name><name><surname>Khajoee</surname><given-names>V</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name></person-group><article-title>CD25+CD4+ regulatory T cells in patients with Kawasaki disease</article-title><source>J Pediatr</source><year>2004</year><volume>145</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">15343196</pub-id></citation></ref><ref id="B139"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyara</surname><given-names>M</given-names></name><name><surname>Amoura</surname><given-names>Z</given-names></name><name><surname>Parizot</surname><given-names>C</given-names></name><name><surname>Badoual</surname><given-names>C</given-names></name><name><surname>Dorgham</surname><given-names>K</given-names></name><name><surname>Trad</surname><given-names>S</given-names></name><name><surname>Kambouchner</surname><given-names>M</given-names></name><name><surname>Valeyre</surname><given-names>D</given-names></name><name><surname>Chapelon-Abric</surname><given-names>C</given-names></name><name><surname>Debre</surname><given-names>P</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Gorochov</surname><given-names>G</given-names></name></person-group><article-title>The immune paradox of sarcoidosis and regulatory T cells</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>359</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">16432251</pub-id></citation></ref><ref id="B140"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Idali</surname><given-names>F</given-names></name><name><surname>Wahlstrom</surname><given-names>J</given-names></name><name><surname>Muller-Suur</surname><given-names>C</given-names></name><name><surname>Eklund</surname><given-names>A</given-names></name><name><surname>Grunewald</surname><given-names>J</given-names></name></person-group><article-title>Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis</article-title><source>Clin Exp Immunol</source><year>2008</year><volume>152</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">18279440</pub-id></citation></ref><ref id="B141"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brusko</surname><given-names>TM</given-names></name><name><surname>Putnam</surname><given-names>AL</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>Human regulatory T cells: role in autoimmune disease and therapeutic opportunities</article-title><source>Immunol Rev</source><year>2008</year><volume>223</volume><fpage>371</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">18613848</pub-id></citation></ref><ref id="B142"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mudd</surname><given-names>PA</given-names></name><name><surname>Teague</surname><given-names>BN</given-names></name><name><surname>Farris</surname><given-names>AD</given-names></name></person-group><article-title>Regulatory T cells and systemic lupus erythematosus</article-title><source>Scand J Immunol</source><year>2006</year><volume>64</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16918689</pub-id></citation></ref><ref id="B143"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Sullivan</surname><given-names>BJ</given-names></name><name><surname>Thomas</surname><given-names>HE</given-names></name><name><surname>Pai</surname><given-names>S</given-names></name><name><surname>Santamaria</surname><given-names>P</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Steptoe</surname><given-names>RJ</given-names></name><name><surname>Kay</surname><given-names>TW</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name></person-group><article-title>IL-1 beta breaks tolerance through expansion of CD25+ effector T cells</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><fpage>7278</fpage><lpage>7287</lpage><pub-id pub-id-type="pmid">16751371</pub-id></citation></ref><ref id="B144"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Morel</surname><given-names>L</given-names></name></person-group><article-title>IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">17182564</pub-id></citation></ref><ref id="B145"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoop</surname><given-names>JN</given-names></name><name><surname>Woltman</surname><given-names>AM</given-names></name><name><surname>Biesta</surname><given-names>PJ</given-names></name><name><surname>Kusters</surname><given-names>JG</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>Janssen</surname><given-names>HL</given-names></name><name><surname>Molen</surname><given-names>RG van der</given-names></name></person-group><article-title>Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response</article-title><source>Hepatology</source><year>2007</year><volume>46</volume><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">17654744</pub-id></citation></ref><ref id="B146"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Muraoka</surname><given-names>M</given-names></name><name><surname>Yamanouchi</surname><given-names>J</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Yasukawa</surname><given-names>M</given-names></name></person-group><article-title>Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>R15</fpage><pub-id pub-id-type="pmid">17284325</pub-id></citation></ref><ref id="B147"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>DE</given-names></name><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Hastings</surname><given-names>WD</given-names></name><name><surname>Bettelli</surname><given-names>E</given-names></name><name><surname>Oukka</surname><given-names>M</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>IL-21 and TGF-beta are required for differentiation of human T(H)17 cells</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>350</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">18469800</pub-id></citation></ref><ref id="B148"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Liew</surname><given-names>FY</given-names></name></person-group><article-title>CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>5012</fpage><lpage>5017</lpage><pub-id pub-id-type="pmid">14607897</pub-id></citation></ref><ref id="B149"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohm</surname><given-names>AP</given-names></name><name><surname>Carpentier</surname><given-names>PA</given-names></name><name><surname>Anger</surname><given-names>HA</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name></person-group><article-title>Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>4712</fpage><lpage>4716</lpage><pub-id pub-id-type="pmid">12391178</pub-id></citation></ref><ref id="B150"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarbell</surname><given-names>KV</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Olson</surname><given-names>K</given-names></name><name><surname>Toy</surname><given-names>P</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title>CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>1467</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">15184500</pub-id></citation></ref><ref id="B151"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagahama</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>E</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Induction of tolerance by adoptive transfer of Treg cells</article-title><source>Methods Mol Biol</source><year>2007</year><volume>380</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">17876110</pub-id></citation></ref><ref id="B152"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>E</given-names></name><name><surname>Sakihama</surname><given-names>T</given-names></name><name><surname>Setoguchi</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells</article-title><source>Int Immunol</source><year>2004</year><volume>16</volume><fpage>1189</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">15237110</pub-id></citation></ref><ref id="B153"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noris</surname><given-names>M</given-names></name><name><surname>Casiraghi</surname><given-names>F</given-names></name><name><surname>Todeschini</surname><given-names>M</given-names></name><name><surname>Cravedi</surname><given-names>P</given-names></name><name><surname>Cugini</surname><given-names>D</given-names></name><name><surname>Monteferrante</surname><given-names>G</given-names></name><name><surname>Aiello</surname><given-names>S</given-names></name><name><surname>Cassis</surname><given-names>L</given-names></name><name><surname>Gotti</surname><given-names>E</given-names></name><name><surname>Gaspari</surname><given-names>F</given-names></name><name><surname>Cattaneo</surname><given-names>D</given-names></name><name><surname>Perico</surname><given-names>N</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name></person-group><article-title>Regulatory T cells and T cell depletion: role of immunosuppressive drugs</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>1007</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">17287424</pub-id></citation></ref><ref id="B154"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minamimura</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Maki</surname><given-names>T</given-names></name></person-group><article-title>CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><fpage>4125</fpage><lpage>4132</lpage><pub-id pub-id-type="pmid">16547248</pub-id></citation></ref><ref id="B155"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Clarkson</surname><given-names>MR</given-names></name><name><surname>Albin</surname><given-names>M</given-names></name><name><surname>Sayegh</surname><given-names>MH</given-names></name><name><surname>Najafian</surname><given-names>N</given-names></name></person-group><article-title>A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>2844</fpage><lpage>2853</lpage><pub-id pub-id-type="pmid">16914538</pub-id></citation></ref><ref id="B156"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>J</given-names></name><name><surname>Rovis</surname><given-names>F</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Afzali</surname><given-names>B</given-names></name><name><surname>Tsang</surname><given-names>JY</given-names></name><name><surname>Garin</surname><given-names>M</given-names></name><name><surname>Lechler</surname><given-names>RI</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Garden</surname><given-names>OA</given-names></name></person-group><article-title>The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro</article-title><source>Int Immunol</source><year>2007</year><volume>19</volume><fpage>785</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">17545278</pub-id></citation></ref><ref id="B157"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imamichi</surname><given-names>H</given-names></name><name><surname>Sereti</surname><given-names>I</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name></person-group><article-title>IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3</article-title><source>Eur J Immunol</source><year>2008</year><volume>38</volume><fpage>1621</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">18493981</pub-id></citation></ref><ref id="B158"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niedbala</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>XQ</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Hueber</surname><given-names>AJ</given-names></name><name><surname>Leung</surname><given-names>BP</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Liew</surname><given-names>FY</given-names></name></person-group><article-title>IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells</article-title><source>Eur J Immunol</source><year>2007</year><volume>37</volume><fpage>3021</fpage><lpage>3029</lpage><pub-id pub-id-type="pmid">17874423</pub-id></citation></ref><ref id="B159"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Bettelli</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Awasthi</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>TB</given-names></name><name><surname>Oukka</surname><given-names>M</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>484</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">17581588</pub-id></citation></ref><ref id="B160"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karandikar</surname><given-names>NJ</given-names></name><name><surname>Vanderlugt</surname><given-names>CL</given-names></name><name><surname>Walunas</surname><given-names>TL</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>CTLA-4: a negative regulator of autoimmune disease</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>783</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">8760834</pub-id></citation></ref><ref id="B161"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Thomson</surname><given-names>AW</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><article-title>What does the future hold for cell-based tolerogenic therapy?</article-title><source>Nat Rev Immunol</source><year>2007</year><volume>7</volume><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">17653127</pub-id></citation></ref><ref id="B162"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>AJ</given-names></name></person-group><article-title>Manipulating regulatory T cells</article-title><source>Cytotherapy</source><year>2007</year><volume>9</volume><fpage>109</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">17453962</pub-id></citation></ref><ref id="B163"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Battaglia</surname><given-names>M</given-names></name><name><surname>Stabilini</surname><given-names>A</given-names></name><name><surname>Migliavacca</surname><given-names>B</given-names></name><name><surname>Horejs-Hoeck</surname><given-names>J</given-names></name><name><surname>Kaupper</surname><given-names>T</given-names></name><name><surname>Roncarolo</surname><given-names>MG</given-names></name></person-group><article-title>Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients</article-title><source>J Immunol</source><year>2006</year><volume>177</volume><fpage>8338</fpage><lpage>8347</lpage><pub-id pub-id-type="pmid">17142730</pub-id></citation></ref><ref id="B164"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horibe</surname><given-names>EK</given-names></name><name><surname>Sacks</surname><given-names>J</given-names></name><name><surname>Unadkat</surname><given-names>J</given-names></name><name><surname>Raimondi</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ikeguchi</surname><given-names>R</given-names></name><name><surname>Marsteller</surname><given-names>D</given-names></name><name><surname>Ferreira</surname><given-names>LM</given-names></name><name><surname>Thomson</surname><given-names>AW</given-names></name><name><surname>Lee</surname><given-names>WP</given-names></name><name><surname>Feili-Hariri</surname><given-names>M</given-names></name></person-group><article-title>Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion</article-title><source>Transpl Immunol</source><year>2008</year><volume>18</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">18158116</pub-id></citation></ref></ref-list></back></article>